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Chronic venous insufficiency (CVI) describes diseases of the lower limb 
veins in which venous return is impaired and varicose veins and skin ulceration may 
develop.  The  roles  of purinergic  signalling  in regulation of vascular tone  in the 
long  saphenous vein  (LSV)  and  in the trophic  changes  occurring  in LSV  muscle 
cells and epidermal keratinocytes  in lower leg skin were  studied.  The purinergic 
role in penile blood flow was also studied, where regulation of penile blood flow 
affects tumescence.
Purinergic signalling was studied using immunohistochemistry, organ bath 
pharmacology  and  electron  microscopy.  P2Xj,  P2Yi,  P2Y2,  P2Y4  and  P2Y6 
receptor  immunoreactivity  was  present  on  LSV  smooth  muscle.  Purine-mediated 
muscle  contractions  were  weaker  in  varicose  veins.  Electron  microscopy  and 
immunohistochemistry findings support the view that smooth muscle cells change 
from the contractile to the synthetic phenotype in varicose veins, associated with an 
upregulation of P2Yi and P2Y2 receptors and a down regulation of P2Xi receptors. 
CVI skin showed a decrease in P2X7 receptor expression and an increase in P2Yj, 
P2Y2  and  P2Xs  receptor  expression  in  different  epidermal  layers.  Mean  skin 
epidermal  area  in  CVI  was  reduced.  Immunohistochemistry  and  RT-PCR 
techniques were used to study the presence of P2Y6 receptors in corpus cavemosal 
tissue.  Using  organ  bath  pharmacology,  P2Y6  receptors  on  cavemosal  tissue 
mediated relaxation which was diminished by a P2Y6 antagonist.
In conclusion it is suggested that the LSV muscle cell phenotype change 
may be a causal factor in the development of varicose veins.  The thinner epidermis 
found  in  CVI  might be  the  result  of the  changes  in  expression  of P2Y  and P2X 
receptors on keratinocytes.  Increased keratinocyte P2Xs receptor activity may,  in 
part,  be  accountable  for  epidermal  thinning  in  CVI.  Purinergic  modulation  of 
human cavemosal smooth muscle cells via the P2Y6 receptor subtype might play a 
physiological role in penile erection.
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9Preface
Receptors for purines and pyrimidines are known to mediate regulation of 
blood vessel tone and long term trophic pathways.  This study was initially intended 
to identify purine receptor variation between control and varicose long saphenous 
vein  (LSV).  Measuring  smooth  muscle  contractions  would  provide  vessel  tone 
related  information  whilst  structural  changes  would  identify  trophic  changes 
occurring.  The first hypothesis was  ‘Purinoceptor changes occur between control 
and  varicose  LSV,  and  these  changes  are  related  to  functional  properties  of the 
smooth muscle, either causal or consequential to varicose veins’.
Reflux within the  superficial veins is thought to be an initial  factor in the 
chain of events during the development of chronic venous insufficiency (CVI).  The 
condition  can  result  in  ulcer  formation  which  may  take  years  to  heal,  can  be 
debilitating  for patients  and  may  require  surgery  for debridement  or  amputation. 
Stripping  of refluxing  superficial  veins  is  a  common  surgical  procedure  in  both 
prevention  of CVI  skin  changes  and  treatment  for  non-healing  ulcers.  The  end 
organ  of CVI,  the  skin,  was  investigated.  Purine-mediated  trophic  changes  to 
keratinocytes  have  been  previously  identified  and  so  our  second  hypothesis  was 
‘Purine-mediated effects on keratinocytes change in CVI skin’.
Having learnt new experimental techniques, I repeated them on penile tissue 
obtained from gender reassignment surgery.  We focused on the P2Y6 receptor as it 
had earlier shown contractile effects in the LSV, is unreported in cavemosal smooth 
muscle (CSM), and P2Y receptor activation is thought to modulate CSM function 
as reported in previous  studies.  Our hypothesis was  ‘The P2Y6 receptor plays  a 
short term role in dilatations underlying penile erection’.  Smooth muscle function 
is  a  possible  target  in  the  treatment  of erectile  dysfunction  and  thus  we  might 
identify new targets for its treatment.
10Chapter 1
IntroductionA) Chronic Venous Insufficiency
The venous system
The venous  system  holds  approximately 2/3rds of the  human body’s blood 
volume1.  Apart from the pulmonary veins and portal vein, it returns deoxygenated 
blood back to the heart.  Their muscular walls allow them to contract and relax so as 
to act as a major reservoir of blood with little change in the venous pressure. Blood 
flows along a pressure gradient from approximately  15-20mmHg in the venules to 
0-6mmHg in the right atrium2.
The blood flow through a vessel can be calculated using Ohm’s law:
Blood  flow   =  Pressure difference between the ends of the vessel + resistance
Venous pressure  within the  abdominal  cavity  is  about 2mmHg.  This  can 
rise to as high as 20mmHg in pregnancy, with large abdominal tumours and with 
ascites.  This  impedes  the  blood  flow  from  the  legs  back  to  the  heart.  Venous 
pressure  within the  legs  must rise  above this pressure  in order for the abdominal 
veins to open and allow the flow of blood back to the heart.
Hydrostatic pressure is caused by the weight of a body of water.  In an adult 
man standing still, the column of blood from his right atrium to his foot creates a 
hydrostatic  pressure  of about  90mmHg  at  the  foot.  However valves  are  located 
within most veins and break up this column.  Muscle contraction, during movement, 
compresses the veins and squeezes blood out.  These valves, when healthy, allow 
blood to flow past them in one direction only, towards the heart.  Contraction of the 
calf muscles compresses the deep veins, forcing blood in a cephalic direction, the 
venous muscle pump.  During relaxation of these muscles, the deep venous system 
fills with blood from the superficial veins along a pressure gradient, via perforating 
and distal veins.  Normal valve function prevents the reflux of blood .  In a walking 
man, the average venous pressure in the foot is 20mmHg.  If he was to stand still 
without contracting his muscles, the venous leg pressure would rise to 90mmHg in 
about 30secs.  A rise in venous pressure increases the pressure within the capillaries 
causing fluid to leak out of the circulatory system into the surrounding tissue.
12Venous  flow out of the  lower limb can be reduced  in three physiological 
settings:
•  Obstruction  of the  blood  flow  from  either  a  thrombus  within  the  blood 
vessel  higher  up  or  from  external  compression  on  the  vein  from  an 
abdominal tumour.
•  Refluxing valves, causing blood to flow back down the leg and accumulate
•  A failure of the muscles to adequately pump blood along the veins, seen in 
patients  with  a reduced  muscle  bulk.  This  could  result  from  insufficient 
exercise or from muscle wasting disorders3.
When a reduction in the flow of venous blood out of the leg is long term, 
blood  accumulates  in  the  leg,  increasing  in  volume  and  thus  pressure.  This  is 
known  as  chronic  venous  hypertension  (CVH)  or  chronic  venous  insufficiency 
(CVI).
CVI can also be divided into primary and secondary
•  Primary CVI results from abnormalities of the valves and the venous wall, 
which leads to reflux.  Inflammatory reactions may play a role.
•  Secondary CVI  is the result of deep vein thrombosis (DVT) or superficial 
vein thrombophlebitis.  Recanalisation  of the  vein  following  these  insults 
may result in obstruction and incompetent valves.
Clinical presentations of CVI
CVI leads to several different clinical features:
•  Increased capillary pressure in the circulatory system forces out fluid at the 
capillaries, resulting in swelling.
•  The increase in pressure within the veins leads to dilated tortuous superficial 
veins known as varicose veins.
13•  The skin can undergo several different changes including varicose eczema, 
pigmentation, fibrosis and ulceration.
•  The leg becomes heavy and painful, especially after standing.
•  Venous claudication, where exercise increases the arterial flow, but due to 
the reduced venous outflow the leg becomes distended and gives a painful 
bursting sensation.  The pain settles after 15 minutes of rest.
Aetiology of CVI
The prevalence of CVI in the adult population is between 5  and  10% and 
costs the National Health Service £230-600 million per year.  Venous ulceration is 
more prevalent in elderly females, and as the female population is greater and has a 
higher  life  expectancy;  its  prevalence  will  continue  to  increase.  Changes  in the 
macrocirculation and microcirculation occur in CVI.
•  Macrocirculation
Competent veins are one of the three mechanisms ensuring adequate venous 
outflow from  the  lower limb.  Reflux  in the  iliofemoral,  long  saphenous  and 
popliteal veins has the  greatest effect on venous  flow4.  Perforating veins  are 
also believed to be to  contributors to  CVI,  as duplex  scanning has  shown the 
number of incompetent calf-perforating veins increase along with the severity of 
CVI5.
Arterial influx into the extremity is thought to be significantly increased in 
CVI.  This  suggests  the  presence  of arteriovenous  fistulae  and  shunting6.  A 
combination of venous reflux and venous hypertension is thought to initiate a 
cascade of inflammatory events.
•  Microcirculation
CVI  affects  the  overlying  skin  and  may  result  in  varicose  eczema, 
lipodermatosclerosis and ultimately venous ulceration.  Erythrocytes extravasate
14into  the  skin,  resulting  in  the  deposition  of  haemosiderin  within  the 
macrophages.  This stimulates melanin production, pigmenting the skin brown. 
The development of ulceration from lipodermatosclerosis is thought to be due to 
enhanced  activity  of matrix  metalloproteinases  (MMP).  MMPs  are  naturally 
occurring  enzymes  that  are  able  to  degrade  the  extracellular  matrix  and 
participate  in  remodeling  of tissues7.  An  underlying  chronic  inflammatory 
process  is  present.  There  are  several  theories  to  the  pathophysiological 
pathway:
a)  The ‘white cell’ trapping theory
Increased venous pressure reduces the perfusion pressure (pressure gradient) 
across the capillary bed causing white blood cells (WBC) to plug the capillaries 
and  red  blood  cells  (RBC)  to  accumulate  proximally.  At  the  post  capillary 
venule the WBCs are forced to marginate by the RBC.  The reduced pressure 
gradient allows the WBC to roll for longer.  Endothelial cells (EC) upregulate 
their  surface  adhesion  molecules  in  venous  hypertension.  There  is 
corresponding upregulation on the WBC of integrin CD1 lb, which increases the 
binding affinity to the ligands on the endothelial  surface.  Thus a reduction in 
physical forces and an increase in the expression of adhesion molecules increase 
the chance of adherence.
The trapped  WBCs  become  activated,  releasing  enzymes  and oxygen-free 
radicals,  damaging EC  and surrounding tissue.  This stimulates the release of 
Vascular  Endothelial  Growth  Factor  (VEGF),  increasing  the  microvascular 
permeability  and  producing  excess  nitric  oxide  (NO),  causing  further  tissue 
damage.  The  trapping  of  WBCs  reduces  perfusion  and  generates  local 
ischaemia which be a may trigger for white cell activation.  This theory was first 
proposed by Coleridge Smith et al8.
Studies of CVH skin show both T-cell and macrophage deposits, suggesting 
a chronic inflammatory process and neutrophil activation.
Claudy  et  al9  proposed  that  leukocyte  activation  also  released  proteolytic 
enzymes  and  elastase  activity  increased.  These  factors  led  to  endothelial
15damage,  increased  vessel  permeability  and  deposition  of pericapillary  fibrin 
from  fibrinogen.  Elastase,  a  lysosomal  constituent  released  from 
polymorphonuclear  cells,  affects  the  role  of  elastin  degradation  in  tissue 
remodeling and wound healing.  Leukocytes were also noted to release tumour 
necrosis factor a (TNF-a) which decreases fibrinolytic activity resulting in the 
formation of a pericapillary fibrin cuff.
b) The fibrin cuff theory
The  pressure  rise  in  CVI  is  thought  to  cause  capillary  elongation10  and 
widening  of the  pores  between  EC11.  This  increases  the  surface  area  for 
exchange  allowing  larger  molecules  such  as  fibrinogen  to  leave  the 
intravascular  compartment.  Fibrinogen  is  converted  to  fibrin,  which 
accumulates  and,  along  with  fibronectin  and  denatured  collagen 
macromolecules,  is  thought to  act  as  a barrier to  oxygen  and  other nutrients, 
resulting in ischaemia and cell death12,13.  However Falanga et al  showed that 
the fibrin cuffs were not a barrier to diffusion, as they observed the cuffs were 
discontinuous around the capillaries, and that venous ulcers healed despite the 
cuff presence on the ulcer border14.
c) The ‘Tran’ hypothesis due to macromolecule leakage
Capillary  distension  or  injury  to  endothelial  cells  due  to  CVH  leads  to 
extravasation of fibrinogen and a 2-macroglobulins from veins to dermis.  These 
macromolecules can cause a functional inhibition of endogenous growth factors, 
eg transforming  growth factor  p  (TGF-p), preventing them maintaining tissue 
integrity and aiding wound repair14.  The abundance of growth factors in venous 
ulcers supports this hypothesis.
16The CEAP classification
CVI is  internationally classified into the  Clinical,  a(E)tiology,  Anatomical 
and Pathophysiological  classification.  This was  developed in  1994  and has been 
expanded in 200315,16.
•  Clinical -  seven classes of clinical signs are described:
Class 0 = no visible or palpable signs of venous disease
Class 1  = telangiectasia and reticular veins, malleolar flare
Class 2 = varicose veins
Class 3 = oedema without skin changes
Class 4a = skin eczema (erythema, scaling, weeping and itching)
Class 4b = lipodermatosclerosis, where the dermis and subcutaneous tissue 
become indurated and fibrosed without the presence of pitting oedema.  The 
skin can become  atrophic,  losing  sweat glands  and hair follicles.  A rigid 
‘woody’  hardness  of the  skin may develop  and  is thought to  resemble  an 
inverted champagne bottle.
Class 5 = previous ulceration now healed 
Class 6 = active ulceration
•  AdOtiology  -   Congenital  (G),  Primary  (P,  unknown)  and  Secondary  (S, 
cause known e.g. post-thrombosis, post-traumatic)
•  Anatomical -  Superficial (S), Deep (D), and Perforating (P)
•  Pathophysiological -  Reflux (R) and Obstruction (O)
Investigations used to detect venous reflux
Hand held doppler enables the clinician to detect reflux in a superficial vein. 
In a standing patient the probe is placed over the vein, the calf squeezed manually, 
and an  audible  reflux  is  listened  for on release  of calf pressure  indicating reflux 
along the vein.  This is then repeated in the presence of a tourniquet, which should
17reduce the reflux  in the  superficial vein when tightened.  This technique, though 
operator dependent, is often satisfactory to detect reflux in the LSV.  In patients in 
whom  further  clarification  of the  site  of reflux  is  required,  duplex  scanning  is 
usually sufficient, where doppler ultrasonography enables the flow along individual 
vessels to be studied.
Venography is an invasive technique where contrast is injected directly into 
varicose  veins  or  superficial  foot veins.  This  can be  useful  in the  obese  patient 
where duplex findings are limited
Calf Muscle Pump
This greatly affects the venous system of the lower leg.  An efficient muscle 
pump induces venous  hypotension on exercise,  with blood pumped back towards 
the  heart.  A  lack  of  this  results  in  venous  hypertension  and  skin  changes. 
Functional calf volume measurements include foot volumetry,  ambulatory venous 
pressure measurements and plethysmography.
Treatment of CVI
This can be divided into conservative and surgical management. 
Conservative management:
•  Leg elevation -  legs elevated to above the level of the heart will aid venous 
drainage of the legs and reduce venous hypertension.  This will help reduce 
leg oedema and improve the rate of ulcer healing.
•  Prevention of risk factors -  avoiding immobility (so as to encourage muscle 
pump activity), reducing obesity and avoiding jobs that require long periods 
of standing still.
•  Graduated  compression  stockings  -   the  application  of  a  graduated 
compression stocking to the lower leg, with greatest pressure at the ankle, 
encourages the flow of venous blood up and out of the leg.  There are four 
classes of compression stockings available:
18Class I -  ankle pressure < 25mmHg 
Class II -  ankle pressure 25-35mmHg 
Class III -  ankle pressure 35-45mmHg 
Class IV -  ankle pressure 45-60mmHg
The  greater  the  degree  of CVI,  the  higher  the  class  of the  compression 
stocking that should be worn.
•  Dressings -  a wide variety exist to aid the healing of ulcers.
•  Treating  infections  -  venous  ulcers  often  become  infected  and  require 
antibiotic therapy.  The  commonest organisms  are  Staphylococcus  aureus, 
Pseudomonas aeruginosa and p-haemolytic streptococci.
•  The  drug  ‘Pentoxifylline’  alone  and  in  combination  with  compression 
stockings  may  contribute  to  ulcer  healing.  Its  actions  are  thought  to  be 
related to inhibition of synthesis of proinflammatory cytokines, inhibition of 
leukocyte  activation  by  reducing  their  adhesion  and  inhibition  of platelet 
aggregation17.  Another  drug  ‘Flavanoid’  may  have  clinical  benefit. 
Flavanoids  are  natural  compounds  that  protect  cells  from  the  effects  of 
hypoxia, decrease the fragility of the vein valves and increase venous tone. 
Flavanoids  also  affect  leukocyte  adhesion  and  free  radical  formation.
1X
Neither of these drugs are widely used in present clinical practice  .
Surgical management:
•  Superficial venous surgery is indicated if significant reflux is present in the 
superficial component.  Reflux in the long saphenous vein (LSV) requires 
high long saphenous vein ligation at the saphenofemoral junction, stripping 
of the LSV and multiple avulsions.  Reflux of the saphenopopliteal junction 
requires saphenopopliteal disconnection and multiple avulsions.  These two 
operations disconnect the long saphenous vein and the short saphenous vein 
respectively  from  the  deep  leg  veins,  and thus  prevent the  blood  flowing
19back towards the foot through the incompetent valves.  This prevents venous 
blood recycling and prevents a build up in venous pressure.
•  Subfascial  Endoscopic  Perforating  Vein  Surgery  -   this  relatively  new 
technique  ligates  the  perforating  veins  connecting  superficial  and  deep 
veins, preventing blood recycling itself in the leg via incompetent valves19. 
This  surgery  avoids  disrupting  the  long  and  short  saphenous  veins  when 
they are competent and functioning normally.
•  Venous valve  reconstruction -  this  is rarely performed  as the  majority  of 
patients  obtain  satisfactory  benefit  form  superficial  venous  surgery  and 
conservative treatments.  This  surgery is complex.  Various methods have 
been described including valvuloplasty (where valves are sutured together to 
render  them  competent  once  more)  and  valve  transplantation  (where 
segments  of  brachial  or  axillary  veins  containing  competent  valves  are 
transposed into the leg vein)  .
•  Venous outflow obstruction can result following a DVT.  Recanalisation of 
the thrombosis commonly occurs, following anticoagulation treatment, and 
collateral veins develop to bypass the venous occlusion.  In patients where 
the venous outflow obstruction persists who develop  symptomatic swollen 
legs and skin changes, bypass surgery using the LSV as a conduit is feasible, 
for example a femoro-femoral cross-over vein graft in patients with an iliac 
vein occlusion21.
•  Skin grafting -  this is suitable for large ulcers, but the ulcer bed must be free 
from  infection  and  slough.  Grafting  aims  to  increase  the  rate  of ulcer 
healing,  however  the  cause  of  the  venous  ulcer  will  still  need  to  be 
addressed.
20i)  Varicose Veins
Varicose  veins  are  dilated tortuous  thickened  superficial  veins.  They  are 
most commonly found in the distribution of the long and short saphenous veins in 
the  lower leg.  Female  patients  often relate  their w  to  pregnancy  and  childbirth 
(male:  female ratio  1.5-3.5  :  l)22.  The prevalence of w  increases with age and a 
hereditary element is thought to exist.
They can be divided into primary and secondary veins.
•  Primary varicose veins (95%) are due to damaged valves leading to reflux of 
blood from deep to the  superficial veins,  increasing the  superficial venous 
pressure.
•  Secondary varicose veins are due to changes in blood flow that lead to back 
pressure and therefore an increase in venous pressure (eg an arteriovenous 
malformation or obstruction due to a pelvic thrombosis).
Several  theories  exist  as  to  the  aetiology  of varicose  veins.  Incompetent 
venous  valves  certainly  occur.  An  inherent weakness  of the  muscle  wall  due  to 
defective  smooth  muscle  and  CT  metabolism  leading  to  vessel  dilatation  is  also 
thought  to  be  a  contributing  factor.  Dilatation  of the  vessel  increases  the  cross 
sectional area.  The valves  do not change in size resulting in  separation of valve 
leaflets  and  a failure  of the  valves  to  close  completely,  allowing  blood to  reflux 
through the  gaps3,23.  This causes an even greater hydrostatic pressure on the vein 
below.  Similar  structural,  biochemical  and  functional  changes  in  varicose 
tributaries  and  in  non  varicosed  veins  from  the  same  patient24  supports  the 
hypothesis  that  abnormalities  within  the  vein  wall  exist  before  the  varicosities 
develop.
21The LSV
The  LSV is an important  structure within the human body.  It commonly 
becomes  varicosed  and  due  to  chronic  venous  hypertension  leads  to  venous 
ulceration3.  It  is  the  most  widely  used  autogenous  venous  graft  due  to  its  thick 
walls, free availability and being the longest vein in the human body.
The LSV is a three-layered structure:
•  Intima:  this  inner layer  consists  of flattened endothelial  cells  resting on  a 
subendothelial  connective  tissue.  This  connective  tissue  consists  of 
collagen, elastin and longitudinal smooth muscle fibres.  This muscle layer 
thickens at the site of valves25.
•  Media:  The media contains  circular smooth muscle  fibres,  interspersed by 
fibroblasts and collagen.
•  Adventitia: This outer layer makes up the bulk of the vein wall.  It contains 
collagen fibres,  fibroblasts and the vasa vasorum.  The vasa vasorum  is  a 
network  of  blood  vessels  supplying  nutrients  to  the  vein  wall.  Thick 
bundles of longitudinal smooth muscle fibres are found in the adventitia  '  .
Structure of varicose veins
Their wall structure varies from hypertrophic to atrophic regions, and there 
is loss of individual layers.
•  Atrophic regions
In atrophic regions the medial SMC and extracellular matrix are diminished. 
The vein wall consists of a thin media lying on the adventitial fibrous tissue.26  Vein 
wall  thickness  varies  to  half  that  of  controls  and  may  represent  aneurysmal 
segments.26
22•  Hypertrophic regions
In  hypertrophic  regions  the  organisation  is  greatly  disturbed.  Smooth 
muscle bundles lose their longitudinal and circular orientation, and are broken up by 
an  accumulation  of  fibrous  tissue.  There  is  an  increase  in  the  quantity  of 
extracellular  matrix  and  in the  number of vasa vasorum  within the  media.  The 
intima is diffusely thickened with both hyperplasia and hypertrophy of the intimal 
SMC and increased and disorganized collagen bundles26,29.
In the hypertrophic media there is reduced staining from outer to inner for 
SM-a-actin and desmin.  Thickened intimal SMC stain strongly for SM-a-actin and 
vimentin26.  Badier-Commander et al  suggested that variations in protein staining 
seen  in  SMC  represent  different  SMC  populations.  They  also  stated  that  the 
alterations of SMC, CT metabolism and BM suggest modulation of the SMC from a 
contractile to a synthetic phenotype, explaining the altered functional properties. 
Electron  microscopy  of  SMC  have  shown  them  to  contain  collagen  fibres, 
suggesting they have taken up a phagocytic role.26
In the w  wall, increases of TGFpi and bFGF have been observed26.  TGFpi 
is known to stimulate the synthesis of ECM components especially collagens and 
elastins.  bFGF is known to be chemotactic and mitogenic for SMC.  The increase 
in these growth factors would explain the increase in ECM and SMC proliferation. 
Furthermore is would support the concept of a proliferative phenotype.
The number of vasa vasorum increase in hypertrophic areas.  Proliferation 
factor  Ki67  has  been  identified  on  endothelial  cells  within  the  vasa  vasorum, 
suggesting angiogenesis occurs in the LSV wall26.  Mast cells accumulating around 
the vasa vasorum may contribute to angiogenesis.
23LSV bypass grafts
As  the  LSV  is  the  longest  vein  in  the  human  body,  is  relatively  easily 
surgically accessible  and  is often expendable,  it  is  commonly used as the bypass 
allograft in surgery eg CABG and revascularization in peripheral vascular disease. 
It is of great value to a surgeon and thus its preservation is important.  Preventing 
varicose changes in the LSV would reduce the incidence of surgical stripping of the 
LSV, maintaining its availability for a bypass graft in later years.
When the LSV is exposed to arterial pressures, histological changes occur 
due to the hypertension (arterial blood in a venous vessel).  These pressure changes 
could be similar in nature to the changes seen in venous hypertension.  It must be 
stressed that these two environments are not identical, as arterial flow is pulsatile, 
causing  both  longitudinal  and  circular  strains.  Arterial  flow  is  also  of a  greater 
pressure and arterial blood differs from venous in its composition.
Vein grafts have a limited life span eg 82% at 5yrs post CABG30.  Factors 
that affect this include the diameter of the distal vascular bed and LSV manipulation 
during harvesting.  Atherosclerosis is a process where endothelial damage leads to 
platelet  aggregation,  lipid  deposition,  smooth  muscle  formation  and  plaque 
formation.  Atherosclerosis is known to occur in arteries, and risk factors include 
smoking,  hypertension  and  hypercholesterolaemia.  Atherosclerotic  lesions  have 
been identified in vein grafts too31.  SMC migration and proliferation are involved 
in  intimal  hyperplasia  of vein  grafts.  Prevention  of LSV  atherosclerosis  would 
further the use of the LSV, reducing the need for revision surgery and for prosthetic 
grafts.  Varicose  LSV,  assuming  it has not been stripped,  may deter the  surgeon 
from using it as a graft.
24ii)  Skin in Chronic Venous Insufficiency
Skin is an organ that consists of two parts, an outer epidermis and a deeper 
underlying dermis.
Epidermis
The epidermis is a multilayered organ.  It consists of keratinised, stratified 
squamous epithelia that divide and flatten as they move outwards away from their 
basal layer.  In areas vulnerable to wear and tear, such as the soles of the feet and 
palms of the hands, the epidermis is extremely thick.  In contrast it is very thin on 
the anterior surface of the forearm.
The deepest layer is the proliferative cell layer.  It comprises of a single row 
of stem cells resting on a basal lamina, which is adherent to the underlying dermis. 
Stem cells divide by mitosis producing the majority of the  cells  in the  epidermis 
(keratinocytes), which are destined to mature into the uppermost layer of keratin.
The  stratum  spinosum,  the  second  deepest  layer,  is  approximately  5 
keratinocyte cells thick.  A strong  supporting framework lies between and within 
the cells.  Lamellar granules are seen in the cells representing initial development of 
lipid rich substances, which continues in the more superficial cells.
The third layer, the stratum granulosum, is characterised by accumulation of 
numerous dense cytoplasmic keratohyalin granules containing proteins that promote 
the aggregation of the tonofilaments to form increasing quantities of keratin.  At the 
same time the nucleus and organelles break down and their destruction results  in 
cells filled with keratin only.  These cells are programmed to destroy their nuclei 
and organelles, yet at the  same time  synthesize keratin and lamellar bodies.  The 
contents  of the  lamellar  granules  in  the  granular  cells  are  discharged  into  the 
extracellular space and provide a lipid layer, establishing a permeability barrier for 
the skin.
The stratum lucidum is seen in thick skin.  It consists of flattened, dead cells 
with abundant keratin proteins.
25The  most  superficial  layer  is  the  stratum  comeum,  consisting  of  dead, 
anucleate  squamous  cells  containing keratin.  It  ranges  from  0.1mm  to >lmm  in 
thickness.  The cells are constantly shed from the surface, and replaced from cells 
arising from the deeper layers.  Transit time  from a stem  cell to desquamation is
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about  1   month  .  The  stratum  comeum  plays  a  crucial  role  as  the  water- 
impermeable  barrier,  protecting  the  underlying  water-rich  internal  organs  from 
environmental dryness.
Dermis
This  consists  of connective  tissue,  blood  vessels,  lymphatic  vessels  and 
nerves.  In general  it is thinner on anterior surfaces  and thinner in women.  The 
dermis is connected to underlying fascia and bones by the superficial fascia.
Hair grows from follicles which are invaginations of the epidermis into the 
dermis.  The hair bulb is the expanded end that lies deep within the dermis.  The 
blood supply to the hair enters via a concavity within the base of the hair bulb, deep 
within the dermis.  Sebaceous glands release secretions, known as sebum, onto the 
shafts of the hairs within the dermis.  Sebum is an oily fluid that helps maintain the 
flexibility of the hair.
Sweat glands are the most deeply penetrating structures  in skin.  They lie 
beneath the dermis in the superficial fascia.  The sweat duct passes from the gland 
to  a  pore  on  the  epidermal  surface.  Sweat  is  secreted  as  a  mechanism  of heat 
control via sympathetic  cholinergic nerves  although adrenaline  and noradrenaline 
also  stimulate  sweat production.  In  severe  conditions,  up to  2L/hr of total  body 
sweat can be produced in man.
26Ulcers
An ulcer is a defect in an epithelial surface.  They can be classified into 4
types:
•  Arterial ulcers
Tissue hypoxia and ischaemia occur as a result of a reduced blood flow and 
result  in  ulceration.  The  most  common  cause  of  reduced  blood  flow  is 
atherosclerosis which affects medium and large sized arteries, however other causes 
include  diabetes,  vasculitis, thalassaemia and  sickle  cell  disease.  Thrombotic  and 
embolic  events  may  accelerate  their  development.  Peripheral  vascular  disease 
describes a condition where there is reduced blood flow to the limbs.  It commonly 
affect  the  lower  limbs  and  produces  symptoms  ranging  from  intermittent 
claudication (calf pain brought on with exercise that is eased with rest) to rest pain 
(constant foot pain that disturbs sleep and is relieved by hanging the foot over the 
edge of the bed).  In severe cases, regular analgesia may be required and gangrene 
develops.  Infected gangrene, known as wet gangrene, requires intervention, either 
surgically  or  radiologically.  If it  progresses  it  will  lead  to  systemic  sepsis  and 
death, unless amputation is performed.
Arterial ulcers commonly occur at limb extremities such as toes, heels and 
over bony prominences.  The ulcers are punched out with well demarcated edges. 
The ulcer base is commonly pale and non-granulating.  Skin surrounding the ulcer 
is often cold, dusky in colour, hairless, thin and shiny.  The peripheral pulses are 
often absent.
•  Venous
As mentioned earlier, venous ulceration is a result of CVI.  50% of venous 
ulcers  are  due  to  superficial  venous  insufficiency  and/or  perforating  vein 
incompetence  with  a normal  deep venous  system.  Venous  ulcers  are  commonly 
persistent and painful, occurring in the gaiter area.  The ulcer bed is often covered 
with a fibrinous  layer mixed with  granulation tissue,  surrounded by  an  irregular,
27gently  sloping  edge.  The  surrounding  skin  is  often  fibrotic,  oedematous  and 
pigmented2.
•  Diabetic
Due to peripheral neuropathy in diabetic patients, these ulcers are commonly 
painless  and  may  go  unnoticed  by  the  person.  These  can  be  divided  into 
neuropathic and neuroischaemic.
Neuropathic  ulcers  develop  in  warm  feet  with  an  adequate  blood  supply. 
Repetitive forces, often from walking, are the commonest cause.  Peripheral nerves 
are damaged due to the diabetes and result in reduced peripheral sensation eg of the 
foot.  A  callus  forms  and if allowed to thicken,  it will  compress underlying  soft 
tissue and lead to ulceration.
Neuroischaemic  ulcers  develop  in  cold  feet  with  an  insufficient  blood 
supply.  Peripheral blood vessels are often absent.  Microvessels become occluded 
due to endothelial cell and basal lamina damage from the diabetes.  They commonly 
develop  on  the  margins  of the  foot,  especially  on  the  medial  aspect  of the  first 
metatarsophalangeal joint.  High  friction  forces  eg  from  ill-fitting  shoes,  lead  to 
blister formation.  This then develops into a shallow ulcer.
•  Others
Ulcers can occur due to dual pathology for example an ischaemic ulcer in a 
diabetic patient who therefore has both microvascular and macrovascular disease. 
Premature  atherosclerosis  occurs  in  diabetics,  hence  these  patients  may  have 
stenosed  large  blood  vessels  along  with  small  blood  vessel  occlusion.  Another 
example  would  include  a  patient  who  has  an  ischaemic  ulcer  and  CVI,  here 
compression  therapy  would  aid  the  CVI  but  worsen  the  ischaemia.  This  can 
complicate ulcer treatments as more than one pathology needs to be addressed at the 
same time in order to aid ulcer healing.  These are sometimes referred to as mixed 
ulcers.  Others conditions where ulcers develop include:
o  Tropical infections (eg yaws and leishmaniasis) 
o  Malignancy (eg basal cell carcinoma and squamous cell carcinoma)
28o  Drugs (eg hydroxycarbamide)
o  Coagulation disorders (abnormalities of coagulation factors can lead 
to skin ischaemia and ulceration eg protein C deficiency, protein S 
deficiency,  antithrombin  3  deficiency,  homocystinaemia and  factor 
V Leiden mutation) 
o  Calciphylaxis (intramural hyperplasia, intravascular calcification and 
thrombosis occur)
o  Many  vasculitis  conditions  can  result  in  ulceration  (eg  Wegener’s 
granulomatosis and polyarteritis nodosa) 
o  Inflammatory  disorders  can  lead  to  ulceration  (eg  pyeoderma 
gangrenosum,  Behcet’s  syndrome,  rheumatoid  arthritis,  systemic 
lupus erythematosus and Sjogren’s syndrome) 
o  Infections  (Leishmania,  syphilis,  tuberculosis,  herpes  simplex, 
cytomegalovirus,  p-haemolytic  Streptococcus  pyogenes  and 
Staphylococcus aureus)
29B) The Penis
Structure and mechanism of penile erection
The  body  of the  human  penis  consists  of three  elongated  erectile  masses 
known as the right and left corpora cavernosa and the median corpus spongiosum. 
The corpora cavernosa forms most of the body of the penis and is composed of an 
array  of  sinusoidal  spaces.  They  are  enveloped  by  a  common  fibrous  tunica 
albuginea and separated by a median fibrous septum.  On the ventral urethral aspect 
lies a wide median groove containing the corpus spongiosum.  The function of the 
corpus  cavernosa  is  purely  erectile.  In  the  flaccid  penis,  cavernous  arteries  are 
contracted and vascular resistance is high.  Relaxation of the muscle tone reduces 
resistance to arterial inflow and brings about tumescence.  The cavernous smooth 
muscle  compliance  increases  and  sinusoids  distend  with  blood,  increasing  their 
dimensions and rigidity.  This increase in size compresses the venous plexus against 
the  tunica  albuginea  which  restricts  venous  outflow,  resulting  in  erection  .  The 
rigidity of the tunica albuginea limits the distensibility.  This results in an increase 
in  length  and  circumference  of the  pendulous  portion  of the  penis  known  as  an 
erection.  The penile volume increases by approximately  100ml on average.  The 
erection is a manifestation of the balance between arterial inflow, venous outflow 
and  dilatation  of  lacunar  spaces.  Tumescence  involves  a  complex  interaction 
between neuronal stimulation of corporal smooth muscle, neurohumoral release of 
specific endothelial contractile and relaxant factors and secondary modulation by a 
variety of neuropeptides and vasoactive modulators34.
Adrenergic  neurotransmission  mediates  the  contraction  of  cavemosal 
smooth muscle  (CSM) through  stimulation of postjunctional  a-adrenoceptors  and
if
maintains the penis in a flaccid state  .  The role of P-adrenoceptors in CSM is still 
controversial,  though  its  presence  has  been  established36.  Autonomic  nervous 
system  (ANS) control  of penile  erection is attributed to the vasodilator effects of 
acetylcholine  (ACh)  and  vasoactive  intestinal  polypeptide  (VIP)  released  from
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parasympathetic nerves  , known to initiate erections in man.  Nitric oxide synthase
30(NOS) has been identified in the same nerve terminals, suggesting a vasodilator role 
of NO.  CSM tone is mediated from outside the corpora by specific transmitters. 
From within the  corpora, NO  mediates  cavemosal  smooth muscle  relaxation and 
endothelin mediates contraction38,39.
Erectile dysfunction
It is hypothesized that  a failure  of the  cavemosal  smooth muscle to relax 
leads to reduced arterial blood flow into the sinusoids, failing to bring about penile 
erection.  Impotence may have  several  causes with treatments  in high demand in 
our  current  society.  Erectile  dysfunction  (ED)  is  common  and  its  incidence 
increases with age, with a prevalence of 70% aged 70 or more40.  ED  shares risk 
factors  with  vascular  diseases  including  smoking,  hypertension,  diabetes, 
hyperlipidaemia,  obesity  and  a  lack  of  exercise41.  Phosphodiesterase  type  5 
inhibitor (PDE5  inhibitor) drugs (sildenafil, tadalafil  and verdenafil) are  currently 
available  to  treat  ED.  PDE5  hydrolyses  cyclic  GMP  (cGMP),  reversing  the 
relaxation of CSM and producing detumescence42.  PDE5 inhibitors help maintain 
intracellular concentrations of cGMP and thus maintain erection.
Alternative treatments for ED  include a vacuum constriction device.  This 
applies negative pressure to the penis that brings on an erection.  This is maintained 
by  an  elastic  band  at  the  base  of the  penis  for  30mins.  Another  treatment  is 
intracavemosal  injections  of prostaglandin  Ei  (alprostadil)  which  relaxes  arterial 
and trabecular smooth muscle, resulting in erection.
Lower urinary tract symptoms (LUTS) describe the clinical presentation of 
bladder  outlet  obstruction  (BOO).  Symptoms  include  urinary  frequency  and 
nocturia, postmicturition dribbling,  weak urinary  stream  and hesitancy.  LUTS  is 
highly prevalent in ageing men, along with ED, and the two are strongly linked43. 
Whilst  epidemiological  studies  show  evidence  that  LUTS  and  ED  are  linked, 
pathophysiological mechanisms exist to support this44:
31Aetiology of LUTS and ED
Nitric Oxide
•  As  stated earlier, NO  is  important in the relaxation of CSM.  Neurogenic 
NO  is  thought  to  be  responsible  for  immediate  relaxation  of the  CSM, 
initiating  erection,  and  endothelial  NO  is  essential  for  maintaining 
relaxation45.  Conditions associated with decreased nerve and endothelium 
function  include  ageing,  hypertension,  smoking,  diabetes  and 
hypercholesterolaemia are all risks factors for ED.
•  NO modulates smooth muscle tone in the prostate and bladder.  NO levels 
are  reduced  in  the  hyperplastic  prostate  and  affects  voiding.  NOS  gene 
expression  is  reduced  with  age  and  in  hyperplastic  prostates46.  The  NO 
theory  suggests  that  reduced  NO  results  is  SMC  proliferation  leading  to 
structural  changes  in  the  prostate  and  increased  prostatic  contraction, 
increasing outlet resistance.
Autonomic hyperactivity
•  Glucose  intolerance,  insulin  resistance,  obesity,  dyslipidaemia  and 
hypertension are part of a metabolic syndrome and are risk factors for ED47. 
Increased ANS activity induces benign prostatic hypertrophy (BPH) in rats, 
and ED.  Observations  have  noted that rats  with autonomic  hyperactivity 
also have prostatic hyperplasia, ED and increased voiding frequency48.
•  ANS  hyperactivity is strongly related to LUTS, secondary to BPH49.  It is 
thought  that  there  is  a  relationship  between  the  increased  sympathetic 
activity associated with LUTS and with ED.
Rho-Kinase activation
•  Rho-kinase  is  thought  to  be  a  calcium  sensitizing  mechanism  in  smooth 
muscle.  Smooth  muscle  contraction  is  a  result  of increased  intracellular
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Ca  concentration  and  mechanisms  exist  to  modify  the  sensitivity  to 
calcium.  Rho-kinase  activation  leads  to  contraction  of  smooth  muscle.
32Rho-kinase inhibitors reduce prostatic  SMC proliferation.  Increased Rho- 
kinase  activity  is  found  in  detrusor muscle  in rabbits  with BOO50,  in the 
CSM  of  rabbits  with  BOO51,  diabetics  and  vascular  smooth  muscle  of 
hypertensives.  A  link between LUTS  and  ED  has  been  speculated  as  an 
increase in Rho-kinase activity.
Pelvic atherosclerosis
•  It is thought that atherosclerosis has a role in the development of BPH die to 
the  similar  risk  factors  the  two  conditions  share  (hypertension,  diabetes, 
hypercholesterolaemia and smoking).
•  Chronic  ischemia  in  rabbits  results  in  CSM  fibrosis,  suggestive  of ED52. 
Chronic  fibrosis also results  in fibrosis and smooth muscle atrophy of the 
bladder53.  With  chronic  ischaemia,  the  increased  production  of TGF-pi 
correlates with the  severity  of fibrosis53.  The  ischaemia also  impairs NO 
mediated relaxation of the prostate and may result in loss of elasticity and 
increase in smooth muscle tone of the prostate54.
•  Atherosclerotic  pelvic  ischaemia  may  be  associated  with  all  the  theories 
mentioned  here,  as  it  induces  hyperactivity  of  the  ANS,  reduces  NOS 
expression and up-regulates Rho-kinase55.
Both  LUTS  and  ED  are  highly  prevalent  in  ageing  men  and  there  are  strong 
associations between the two conditions.  Treating LUTS may help improve ED.
33C) Purinergic Signalling
Purines and purinoceptors
A  seminal  paper  describing  the  potent  extracellular  actions  of  adenine 
compounds was published by Drury and  Szent-Gyorgyi56  in  1929.  Buchthal and
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Folkow  found that ACh-evoked contraction of skeletal muscle was potentiated by 
exposure to adenosine  5’-triphosphate  (ATP) and in  1959, Holton58  demonstrated 
the release of ATP during antidromic  stimulation of sensory nerves  supplying the 
ear artery, hinting at a transmitter role of ATP in the nervous system.  The concept 
of purinergic  neurotransmission  was  first  put  forward  by  Bumstock  in  197259. 
Purines and pyrimidines have been shown to play important roles within mammals, 
in particular within the cardiovascular system60.
Implicit in the concept of purinergic neurotransmission was the existence of 
postjunctional  purinergic  receptors61.  Bumstock62  proposed  a  basis  for 
distinguishing two types of receptor: PI  and P2.  Adenosine acts on the G protein- 
coupled  PI  receptors,  of  which  there  are  four  subtypes:  Aj,  A2A,  A2B,  A3. 
Adenosine is an ectoenzymatic breakdown product of ATP.
In  1985,  a basis for distinguishing two types of P2 purinoceptor, P2X and 
P2Y, was proposed63.  A new nomenclature system was put forward in 1994 which 
is  now  widely  accepted64,65.  P2  receptors  are  activated  by  the  extracellular 
nucleotides ATP, adenosine diphosphate (ADP),  uridine  5’-triphosphate (UTP) or 
uridine  diphosphate  (UDP).  P2  receptors  have  now been  subdivided  into  seven 
P2X(i-7)  ligand-gated  ion  channel  receptors  and  eight  P2Y(i>   2,  4,  6,  11,  12,  13,  14)66 
receptors.  P2X and P2Y receptors are often expressed in the same cells.
P2X receptors are characterized by 2 transmembrane domains with a large 
extracellular  loop where  10  cysteines  are  preserved;  both N  and C  terminals  are 
intracellular.  A major property of the P2Xj  receptor is its mimicry of the agonist 
actions  of  ATP  by  a,p-methylene  ATP  (a,P-meATP).  The  P2Xi  receptor  is 
expressed predominantly in smooth muscle.  P2Xj  and P2X3 receptors desensitize 
in milliseconds, the continued presence of ATP eliciting a reduction in current.  In
34contrast,  P2X2  and  P2X4  receptors  desensitize  slowly67.  There  are  no  known 
selective P2X2 receptor agonists or antagonists.  P2X2, P2X4 and P2X6 receptors are 
mainly distributed within the central nervous system (CNS).  2-MethylthioATP is 
as potent as or more potent than ATP at P2X3 receptors.  P2X3  is solely found in 
sensory  neurones.  ATP-evoked  currents  at  P2X4  receptors  are  potentiated  by 
ivermectin68.  ATP-evoked currents at rat P2X5 receptors are small in amplitude and 
the  receptor  shows  little  desensitization67.  The  P2X6  receptor  appears  to  be  a 
‘silent’  subunit  as  no  currents  are  evoked  by  ATP  when  it  is  expressed  as  a 
homomultimer; it appears to only be functionally expressed as a heteromultimer eg 
P2X2/6 and P2X4/6.  One main feature of the P2X7 receptor is the ability to become 
permeable  to  large  cations  following  prolonged  exposure  to  high  ATP 
concentrations, and to undergo a channel to pore conversion allowing the passage of 
large  dye  molecules  such  as  ethidium,  usually  leading  to  cell  death69.  2’,3’-0- 
(benzoyl-4-benzoyl)-ATP is a potent P2X7 receptor agonist.  The P2X7 receptor is
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dominant within the immune system and is involved in cell death  *   .
P2Y receptors are single protein receptors, with an extracellular N-terminus 
and intracellular C-terminus.  Each P2Y receptor binds to a G protein.  Following 
nucleotide  activation,  they  either  activate  phospholipase  C  releasing  intracellular
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Ca  ions  or  affect  adenylyl  cyclase  and  alter  cyclic  adenosine  monophosphate 
(cAMP) levels73.  Most of the P2Y receptor subtypes still lack potent and selective 
agonists  and  antagonists,  though  ADPpS  is  a  potent  P2Yj,  P2Yi2  and  P2Yn 
receptor agonist.  P2Y  responses  occur not only within the  neuronal  system,  but 
also  in  non-neuronal  and  non-muscular  cell  types  eg  endothelial  cells.  P2Y 
receptors  also  mediate  long  term  effects  including  DNA  synthesis  and  cell 
proliferation.  ADP has a greater potency than ATP for the P2Y1   receptor in most 
species.  The most potent and selective agonist is the N-methanocarba analogue of 
2-Methylthio  ADP  (2-MeSADP),  MRS2365,  whilst  effective  selective  P2Yi 
receptor  antagonists  include  MRS2179,  MRS2279  and MRS2500.  P2Yi  mRNA 
expression  is  highest  in  the  brain,  prostate  gland  and  ovary74,75.  The  y- 
thiophosphate,  UTPyS,  is  a  potent  P2Y2  receptor  agonist  and  suramin  a  weak 
antagonist.  P2Y2  receptor  activation  increases  the  synthesis  and/or  release  of
35arachidonic acid, prostaglandins and NO.  P2Y2 receptors play a role in the wound 
healing  process  and  receptor  expression  in  smooth  muscle  cells  (SMC)  is  up- 
regulated by agents that mediate inflammation76.  UTP is the most potent activator 
of the human P2Y4 receptor, whilst Reactive Blue 2 only partially blocks it.  P2Y4
77
mRNA is most abundant in the intestine  .  UDP and the more selective uridine P- 
thiodiphosphate are both agonists of the P2Y6 receptor.  The P2Y6 receptor is slow 
to  desensitize  and  is  highly  expressed  in  the  spleen,  intestine,  liver,  brain  and 
pituitary78,79.  ATPyS  is  a  more  potent  agonist  than  ATP  at  the  P2Yn  receptor, 
whilst suramin behaves as a competitive antagonist.  The 5’-triphosphate derivative 
AR-C69931MX compound,  named cangrelor,  is  an antagonist to both P2Yi2  and 
P2Yb receptors.  The P2Yn receptor is present on platelets, the brain,  SMC  and 
chromaffin cells80'82.  The P2Yn receptor is present in the spleen, placenta,  liver, 
heart,  bone  marrow,  monocytes  and  T-cells83,84.  The  P2Ym  receptor,  a  recent 
discovery, has no known selective antagonists, though UDP, UDP-galactose, UDP- 
glucuronic acid and UDP-N-acetylglucosamine are agonists.
Different  receptor  subunits  can  be  coexpressed  on  the  same  receptor, 
producing a heteromeric receptor.  These receptors have properties reflecting both 
subunit  types.  The  P2X2/3  receptor  is  potentiated  by  a  low  pH  and  does  not 
desensitize rapidly, reflecting the homomeric P2X2 receptor properties, whilst like 
the homomeric P2X3 receptor, it is blocked by 2’, 3’-0-(2,4,6-trinitrophenyl)-ATP, 
pyridoxal-phosphate-6-azophenyl-2’, 4’-disulphonic acid (PPADS) and suramin85.
Receptors on vascular endothelium
Both P2Y  and P2X receptors  expressed on EC  mediate vasodilatation via 
NO61.  The  location of P2Y receptors on endothelial cells  forming the  innermost 
layer  of blood  vessels  implies  that  these  receptors  are  important  as  sensors  and 
effectors  of response  to  local  changes  of purines  in  blood.  Thus  endothelium 
dependent vasodilatation is likely to be linked to the release of purines at the intimal 
surface from erythrocytes and from endothelial cells.  In many blood vessels P2Y1
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and  P2Y2  receptors  coexist  on  EC  in  variable  proportions  .  Shear  stress  and 
hypoxia stimulate vascular EC release of ATP and UTP into the lumen, agonists to 
endothelial P2Yj and P2Y2 receptors respectively87,88.  Studies on human umbilical 
veins  have  identified  P2X*,  P2Yi,  P2Y2  and  P2Yn  on  EC.  It  is  thought  they 
mediate the release of NO, endothelium-dependent hyperpolarizing factor (EDHF) 
and tissue-type plasminogen activator (t-PA).  P2Y4 and P2Y6 were also identified 
but showed weak expression89,90. P2X4 receptors are thought to be involved in cell 
permeability and adhesion91.  High levels of P2X4 receptors have been reported on 
saphenous  vein  EC  and  low  levels  on  mammary  arteries  .  Yamamoto  et  al 
demonstrated  P2X4  receptor-mediated  vascular  dilatation  in  a  NO-dependent 
manner93.  Functional  P2Yi,  P2Y2,  P2Y4  and  P2Y6  receptors  on  EC  mediate 
relaxation in the thoracic aorta94.  In most blood vessels there is a continuous basal 
release of NO from EC which controls smooth muscle contractility and sets a basal 
vasodilator tone.  Removal of the endothelium or blockade of endothelial cell NO 
formation (with NOS  inhibitor) inhibits endothelium dependent vasodilatation via 
P2 receptors and facilitates vasoconstrictor actions mediated by P2 receptors on the 
underlying SMC.
Receptors on vascular smooth muscle
P2X receptors mediate vasoconstriction to ATP released as a cotransmitter 
with noradrenaline (NA) and neuropeptide Y (NPY) from sympathetic nerves (see 
below).  P2Xj  receptors,  potently  activated  by  a,P-meATP,  are  the  principal 
subtype61.  This component of the sympathetic response can be blocked by purine 
receptor antagonists but not by adrenoceptor antagonists.  Vascular smooth muscle 
P2X2 and P2X4 as well as P2Y2, P2Y4 and P2Y6 receptors have also been identified 
that mediate vasoconstriction in some vessels60,86,95,96.
Some  SMC,  in particular those  in  coronary  arteries,  express  vasorelaxant 
P2Y receptors97.  These  receptors  are  most potently activated by 2-MeSATP  and 
ADP, suggesting that they are likely to be P2Y1  receptors.
37Pi.2 and P2Y receptors  on  SMC  have roles  in  control  of cell proliferation. 
The change from a vascular SMC of contractile phenotype to a synthetic phenotype 
is a central pathophysiological process in the development of atherosclerosis and in 
restenosis  after  angioplasty.  Several  changes  in  gene  expression  take  place,  for 
example,  the  cells  lose  their  ability  to  contract,  synthesize  ECM  and  express 
receptors for growth factors98,99.  P2Xi receptors are down regulated and P2Yj and 
P2Y2 receptors upregulated when the vascular SMC changes from a contractile into 
a synthetic phenotype100.  The upregulation of P2Y2 receptor suggests it may be an 
important mediator of cellular growth, and have other functions such as stimulation 
of matrix proteins or release of growth factors100.  Increased expression of the P2Y2 
receptor  may  mediate  atherosclerosis  and  neointima  formation  after  balloon 
angioplasty101.  UDP stimulates mitogenesis through activation of P2Y6 receptors, 
hence P2Y6  is thought to be of importance  in regulating vascular smooth muscle 
growth and differentiation102.
Fig 1.1 : Short term purinergic signalling controlling vascular tone.  This illustration 
summarizes the location and action of the main purine receptors in blood vessels. 
Perivascular  nerves  in  the  adventitia  release  ATP  as  a  cotransmitter:  ATP  is 
released with NA and NPY from sympathetic nerves to act on smooth muscle P2Xi, 
P2X2 and P2X4 receptors, resulting in vasoconstriction;  it is released with CGRP 
and SP from  sensory nerves during axon reflex activity to  act on smooth muscle 
P2Y  receptors  resulting  in  vasodilatation.  Ai  receptors  on  nerve  terminals  of 
sympathetic  and  sensory  nerves  mediate  adenosine  (arising  from  the  enzymatic 
breakdown of ATP) modulation of transmitter release.  P2X3 receptors are present 
on  a  subpopulation  of sensory  nerve  terminals.  A2  receptors  on  vascular  SMC 
mediate vasodilatation.  EC release ATP and UTP during shear stress and hypoxia 
to act on P2Yj, P2Y2, P2Y4 and P2Y6 receptors leading to the production of NO and 
subsequent  vasodilatation.  Platelet  aggregation  releases  ATP  which  acts  on  EC 
receptors.  Platelets possess  P2Yi  and P2Yi2  ADP-selective  receptors  along with 
P2Xj receptors.  Immune cells posses P2X7, P2Xi, P2Yi and P2Y2 receptors.  P2X2,
38P2X3  and  P2X4 receptors  have  been  identified  on  EC  membranes.  (Reproduced 
from Bumstock G.  Purinergic  signaling and vascular cell proliferation and death. 
Arterioscler Thromb Vase Biol. 2002;22:364-373103).
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Receptors on perivascular nerves
Blood vessel  adventitia contains perivascular nerves which  express purine 
receptors.  Activation  of  A1  receptors  prejunctionally  on  the  terminals  of 
perivascular  sympathetic  and  sensorimotor  nerves  mediates  inhibition  of 
neurotransmitter release.  ATP release and breakdown acts on A1 as auto regulation 
of ATP neurotransmission.  P2Yi receptors on postganglionic sympathetic neurons 
mediate  neurotransmission  by  involvement  in  feedback  inhibition  of co  released 
ATP,  NA  and  NPY.  Heteromeric  P2X2/3  receptors  may  be  involved  in 
nociception61.
39Receptors on platelets
P2Yi2 receptors are  almost exclusively found on platelets and (along with 
P2Xi and P2Yi) mediate aggregatory properties80,104.  Clopidogrel, a P2Yi2 receptor 
competitive antagonist, is now readily prescribed as an antithrombotic agent80.  A2A  
receptors  on  platelets  inhibit  aggregation.  This  may  be  significant  in  the 
autoregulation  of  platelet  aggregation  from  ADP  and  ATP  released  from 
platelets105'108.  NO is able to inhibit platelet adhesion to the EC surface and inhibit 
platelet aggregation via an ADP mediated pathway109.
ATP, ADP and UTP are released from platelets upon platelet aggregation, 
when there is damage to the function or integrity of the endothelium.  Subsequent 
activation  of P2  receptors  on  SMC  underlying  the  endothelium  results  in  severe 
vasoconstriction and potentially ischaemia61.
Ectonucleotidases
ATP  is  rapidly  degraded  to  ADP,  AMP  and  adenosine  by 
ectonucelotidases110.  Adenosine  is  further  metabolized  to  uric  acid. 
Ectonucleotidases are situated at the surface of cells and in the vas deferens may be 
coreleased with ATP.  This limits the action of ATP at P2 receptors by removing it 
through enzymatic breakdown, but it can evoke opposite effects via the actions of 
the breakdown products ADP and adenosine at P2Y and PI receptors respectively60.
The role of purines in inflammation
Purines acting on purinoceptors have a broad range of functions including 
pro  and  anti-inflammatory  actions,  killing  intracellular  pathogens  by  inducing 
apoptosis  of host  macrophages,  chemoattraction  and cell  adhesion111,112.  ATP  is 
involved  in  the  development  of inflammation through  several  actions:  release  of 
histamine  from  mast  cells,  provoking  production  of  prostaglandins  from  P2Y 
receptors113; and the production and release of cytokines from immune cells113,114.
40Adenosine is released at sites of inflammation and has anti-inflammatory effects via 
several  mechanisms.  It  inhibits  neutrophil  rolling  and  adhesion  to  vascular 
endothelium,  it  decreases  oxygen  free  radical  production  by  neutrophils  via 
activation of A2A  receptors, and via Ai  and A2A  receptors it affects endothelial cell 
permeability115.  Adenosine  also  inhibits  macrophage  production  of the  cytokine 
TNFa and suppresses TNFa mRNA expression115.
The P2X7 receptor mediates cytokine release,  generates NO, the killing of 
intracellular pathogens  and cytotoxicity116.  P2X7 receptor stimulation on alveolar 
macrophages  triggers  activation  of interleukin-1   (IL-1)  and  IL-6  cytokines  and
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granulomatous reactions  .  In contrast, ATP and ADP inhibit cytokine generation 
by human mast cells through P2Y receptors118.  Stober et al have provided evidence 
for P2X7 receptor mediated  cytotoxic  actions  of ATP  on macrophages  and P2Y2 
receptor mediated bacteriocidal effects of ATP119.  P2X7, P2Yi  and P2Y2 receptor 
expression  on  macrophages  and  giant  cells  increase  during  an  inflammatory 
reaction demonstrating a regulatory function in inflammation120.
Atherosclerosis  is  considered  to  be  an  inflammatory  disease.  The 
inflammatory mediator IL-1 p increases P2Y6 receptor mRNA expression102.  As the 
P2Y6 receptor is involved in the regulation of vascular smooth muscle growth and 
differentiation,  it  is  thought  to  play  a  role  in  the  formation  of  atherosclerosis. 
Extracellular ATP inhibits the activation of CD4+ T lymphocytes via P2 receptors, 
suggesting  a  possible  therapeutic  target  for  topical  immunosuppression  in  some
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inflammatory  diseases  .  ATP  is  thought  to  regulate  the  trafficking  of specific 
dendritic cells via P2Yn receptors122.  The migration of dendritic cells to lymphoid 
tissue  from  the  site  of the  captured  antigen  is  required  for  the  induction  and 
regulation of immune responses.  P2Y1 1  receptor targeting may have a therapeutic 
role in improving migration of the dendrites123.
41Long term trophic effects of purines
It  is  now  known  that  purines  play  a  major  role  in  cell  proliferation, 
differentiation  and  death  in  many  tissues.  These  changes  are  long  term,  in 
comparison  to  their  fast  P2X  mediated  vasoconstriction  effects  on  SMC.  In 
vascular SMC and EC, purines play an important role in the development of intimal 
thickening during atherosclerosis and in the growth of new vessels that occur during 
wound  healing  and  in  tumours98,124,125.  Purines  play  important  roles  in  the 
maintenance  of the  keratinocyte  epidermal  layer in  skin126.  ATP  and  ADP  have 
synergistic actions with a number of growth factors eg. angiotensin II, endothelin-1, 
NADR,  NPY,  5-hydroxytryptamine,  platelet  derived  growth  factor,  insulin  like 
growth  factor  and  basic  fibroblast  growth  factor127.  Extracellular  ATP  has 
mitogenic  actions  with  other  cell  types  including  fibroblasts  and  endothelial 
cells128,129.  P2Yg  receptors  in  the  frog  embryo  (not  a  recognized  mammalian 
receptor) are  involved  in the  development of the  neural plate  and P2Yi  receptors 
play  role  in  cartilage  development  in  limb  buds  and  in  the  development  of the 
mesonephros130.
42Fig  1.2 :  Schematic of long term (trophic) actions of purines released from nerves, 
platelets  and  endothelial  cells (which  also release UTP)  acting on  P2  receptors  to 
stimulate  or  inhibit  cell  proliferation.  ATP  release  as  a  cotransmitter  from 
sympathetic  nerves  and  sensory-motor  nerves  (during  reflex  axon  activity) 
stimulates  smooth  muscle  proliferation  via  P2Y2  and/or  P2Y4  receptors  via  a 
MAPK cascade, while adenosine resulting from enzymatic breakdown of ATP acts 
on A2 receptors to inhibit cell proliferation (via elevation of cAMP).  ATP and UTP 
released  from  endothelial  cells  stimulate  both  endothelial  and  smooth muscle  cell 
proliferation via P2Yi,  P2Y2  and P2Y4  receptors.  Adenosine  resulting  from  ATP 
breakdown  acts  on  A2  receptors  to  stimulate  endothelial  cell  proliferation  and 
regulate  release  of  PDGF  from  platelets.  (Reproduced  from  Bumstock  G. 
Purinergic signaling and vascular cell proliferation and death.  Arterioscler Thromb 
Vase Biol. 2002;22:364-373105).
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43Purinergic cotransmission and neuromodulation
The  concept that  one  neuron releases  only  a  single  transmitter,  known  as 
‘Dale’s  principle’,  was  suggested  in  1935131  and  governed  our  understanding  of 
neurotransmission  at the  time.  Chemical  transmission was  thought to  consist  of 
adrenergic  nerves  releasing  NA  and  cholinergic  nerves  releasing  ACh.  In  the 
1950’s  hints  of  acceptance  to  this  theory  appeared  and  in  1976  Bumstock132 
challenged the principle with an article entitled ‘Do some nerve cells release more 
than  one  transmitter?’.  The  concept  of cotransmission  thus  materialised,  where 
more than one transmitter is synthesized, stored and released by one nerve eg amino 
acids, purines, NO, peptides and monoamines.  Further research has demonstrated 
the role of ATP as a cotransmitter in sympathetic, parasympathetic, sensory-motor 
and enteric non-adrenergic, non-cholinergic  (NANC) inhibitory nerves133.  Not all 
colocalised  substances are necessarily cotransmitters;  instead they can act as pre- 
and/or  post-junctional  neuromodulators  of  the  release  and  actions  of  the
133 neurotransmitters  .
A  branching  plexus  of  varicose  nerve  fibres  form  the  autonomic 
neuroeffector  junction.  The  terminal  axons  consist  of  a  series  of  varicosities 
separated by intervaricose regions.  Upon depolarization the varicosities release ‘en 
passage’ their stored neurotransmitters, which pass across the junctional cleft acting 
on the muscle bundles134.  The SMC are in electrical continuity with each other via 
gap junctions  (low resistance  pathways),  thus  nerve  impulses  in the  perivascular
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nerves are propagated throughout the media via these channels  .
NA  is  a  neurotransmitter  in  sympathetic  nerves  and  acts  on  a  and  p 
adrenoceptors,  ai-adrenoceptors mediate excitation while p-adrenoceptors mediate 
inhibition.  NA,  ATP  and  NPY  are  cotransmitters  in  sympathetic  nerves.  The 
release  of  tritium  from  taenia  coli  preincubated  in  [3H]adenosine  (which  is 
converted  to  [ HJATP)  following  sympathetic  nerve  stimulation  was  the  first 
indication that ATP might be released from these nerves136.  Langer et  al137 then 
suggested  that  the  substantial  residual  NANC  response  of  the  cat  nictitating 
membrane observed after depletion of NA by reserpine was due to the release of
44ATP remaining in sympathetic nerves.  Early studies demonstrated cotransmission 
of NA  and  ATP  in  vas  deferens,  a  tissue  with  a  high  density  of  sympathetic 
nerves138,139.  Cotransmission of NA  and ATP  in perivascular sympathetic nerves 
has now been demonstrated in rat tail artery140, rabbit saphenous141  and pulmonary 
arteries142,  and dog basilar143 and mesenteric arteries144.  Studies have demonstrated 
a  biphasic  response  on  sympathetic  stimulation;  an  initial  fast,  transient 
depolarization  or  excitatory junction  potential  (EJP)  and  contraction  of vascular 
smooth muscle is followed by a slow, prolonged depolarization and slow relaxation. 
The  EJP  and  slow  depolarization  are  mimicked  by  the  effects  of ATP  and NA, 
respectively.  Variations in the proportions of NA and ATP utilized by sympathetic 
nerves  exist.  The  purinergic  component  is  optimal  with  short  bursts  of  low 
frequency  stimulation,  whereas  longer  durations  of  higher  frequency  favour 
adrenergic  transmission145.  NPY  is  often  co-stored  with  NA  in  large  granular 
vesicles  in sympathetic  nerves.  NPY has  few postjunctional  actions,  although at 
high  concentrations  it  can  produce  contraction.  Neuromodulation  is  the  main 
function  of NPY;  pre-synaptically  it  reduces  the  release  of NA  and  ATP,  post- 
synaptically it augments their actions146.
ACh, the main post-ganglionic neurotransmitter in parasympathetic nerves, 
acts on muscarinic receptors.  In 1981, Lundberg147 demonstrated cotransmission of 
ACh and VIP  in parasympathetic  nerves  on cat  salivary  glands.  Low  frequency 
nerve stimulation releases ACh which increases salivary secretion from acinar cells 
and  elicits  minor  dilatation  of  the  gland’s  blood  vessels.  High  frequency 
stimulation releases VIP causing marked vasodilatation, and whilst it has no direct 
effect on acinar cells, it acts as a neuromodulator enhancing both the postjunctional 
effect  of ACh  on  acinar  cell  secretion  and  increasing  ACh  release  from  nerve 
varicosities  via  prejunctional  receptors.  Parasympathetic  nerves  supplying  the 
urinary bladder utilize  ACh and ATP  as  cotransmitters  in variable proportions  in 
different  species148,149.  ATP  acts  through  P2X  receptors  to  produce  a  fast 
contraction, while ACh mediates a slow response150.
Calcitonin  gene-related  peptide  (CGRP)  and  substance  P  (SP)  have  been 
shown to coexist in sensory nerve terminals in perivascular nerves151  and in large
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granular  vesicles  .  CGRP  release  from  sensory-motor  efferent  nerves  in  rat 
mesenteric arteries mediates vasodilatation while SP is not co-relased153.  In guinea 
pig skin, unmyelinated sensory neurons contain cholecystokinin, CGRP and SP154. 
There is evidence that ATP coexists in some sensory nerve terminals with SP and 
CGRP155.  The  role  of these  nerves  during  axon reflex to  many  organs  is  motor 
rather than sensory156.
Intrinsic neurons exist in most of the major organs of the body.  In the gut 
and heart, some of these are derived from neural crest tissue and thus differ from 
the parasympathetic and sympathetic nervous system.  They appear to participate in 
local  reflex  actions  independent  of the  CNS.  A  subpopulation  of this  enteric 
nervous  system  provides  NANC  inhibitory  innervation  of  the  gastrointestinal 
smooth muscle.  Three major cotransmitters are released from these nerves.  ATP 
produce  fast  inhibitory junction potentials  (IJP), NO  produces  slower IJPs,  while 
VIP  produces  slow tonic  relaxations157.  Intrinsic  cardiac neurons  have  identified 
subpopulations that contain and/or release the cotransmitters ATP, NO, NPY ACh 
and serotonin, many of which produce potent vasomotor actions158-161.
Although  single  presynaptic  action  potentials  release  small  molecule 
neurotransmitters,  trains  of  impulses  are  needed  to  release  neuropeptides.  In 
sympathetic and parasympathetic cotransmission, ATP is released at low frequency 
stimulation,  whereas  the  larger  molecules  of  NA,  ACh  and  neuropeptides  are 
released at high frequencies  162>163.  Neurons  containing  several  neurotransmitters 
may  have  more  than  one  target.  In  the  acinar  cells  of the  salivary  gland,  ACh 
release,  following low frequency stimulation, produces  saliva secretion and minor 
vasodilatation, whereas high frequency stimulation releases VIP  causing powerful 
vasodilatation and enhancing ACh-induced saliva secretion164.  Cotransmitters can 
feed back on presynaptic receptors and neuromodulate their own release.  Both NA, 
via  a2-adrenoceptors,  and  ATP,  via  PI  receptors  following  its  breakdown  to 
adenosine,  can  prejunctionally  modulate  sympathetic  cotransmission165’166. 
Postjunctionally  cotransmitters  may  work  synergistically  eg  ATP  and  NA  on 
smooth muscle  in the vas  deferens167,  and  antagonistically  eg nicotinic  a3p4  and 
P2X2 in Xenopus oocytes168.  Some cotransmitters have opposing actions on their
46postjunctional  cells.  Brain-derived  neurotrophic  factor  (BDNF)  alters 
neurotransmitter  release  in  cardiac  sympathetic  neurons.  BDNF  increases  the 
release  of ACh  and reduces NA  release to  cause  a rapid  shift  from  excitatory to 
inhibitory transmission169.
There is increasing evidence that the expression of autonomic transmission 
can  alter  in  disease.  ATP  is  a  significant  cotransmitter  in  sympathetic  nerves 
supplying hypertensive blood vessels and this purinergic component is increased in 
spontaneously hypertensive rats61.  The parasympathetic purinergic nerve-mediated 
component  of  contraction  on  the  human  bladder  is  increased  to  40%  in 
pathophysiological  conditions  such  as  interstitial  cystitis  and  outflow 
obstruction170,171.  Perivascular nerves  in penile vessels containing the vasodilator 
VIP  are  reduced  in  diabetic  man172,  whilst  VIP  expression  is  increased  in  the 
diabetic rat gut173.  In Crohn’s disease there is a transmural increase in VIP in the 
diseased  gut174.  The  ANS  shows  marked  plasticity.  The  expression  of 
cotransmitters  and  receptors  shows  dramatic  changes  during  development  and 
ageing, in nerves that remain after trauma and in disease conditions130.
47D) Purinergic signalling in the long saphenous vein, 
skin and the penis
Purinergic signalling in the LSV
Perivascular  nerve  fibres  lie  at  the  media-adventitia  border  forming  the 
neuroeffector junction.  There is an extensive network of branching terminal fibres 
that lack a  Schwann cell  covering.  These  contain varicosities  (l-2pm  diameter), 
separated  by  intervaricose  regions  (0.1-0.3  pm  diameter)175,  where 
neurotransmitters  are  stored  and  released  by  the  depolarizing  effect  of  nerve 
impulses along the axons.  For many years, ACh and NA were thought to be the 
only neurotransmitters.  Many neurotransmitters have now been identified including 
ATP  as  wells  as  Substance  P,  CGRP,  NO  and  serotonin176.  The  SMC  are  in 
electrical  continuity with each  other via  gap junctions,  there  is  no postjunctional 
specialization, thus they differ from synapses at motor end plates in striated muscle 
and within ganglia27,177.
SMC are specialised for continuous contraction of low force, in comparison 
to skeletal muscle, which is specialized for greater force of shorter durations.  The 
muscle  contracts  as  a  whole  mass  rather  than  individual  motor  units.  Muscle 
contractions occur from stimulation via the ANS, hormones and local metabolites. 
Contractions can be independent of neurological innervations.  SMC are relatively 
small with a single nucleus.  The fibres are bound together in irregular branching 
fasciculi178.
Purinergic  cotransmission  has  previously  been  demonstrated  in  the  LSV. 
ATP  and  a,P-meATP  contract  the  circular  smooth  muscle  in  vein  rings.  This 
response  is  markedly  inhibited  in the  presence  of P2X receptor antagonists179,180. 
On control LSV circular rings, Boma et al demonstrated contractile effects of P2Xj, 
P2Y2,  P2Y4  and  P2Y6  and  detected  mRNA  for  P2Xh  P2X7,  P2Yh  P2Y2,  P2Y4, 
P2Y6  and  P2Yn181.  Ray  et  al92  identified  P2X(i.7)  and  P2Y2  receptors  on  LSV
48endothelial  cells92  while  in  addition  Conant  et  al182  detected  ?2Y\  receptors  on 
endothelial cells.  Northern blot analysis of total RNA from LSV  smooth muscle 
detected the P2X7 receptor, where its activation formed membrane pores permeable 
to large molecules183.
Ziganshin  et  al  compared  purine-mediated  contractions  in  varicose  vein 
rings with veins obtained from atherosclerotic legs, showing stronger contractions 
to  ATP,  a,p-methylene  ATP  and  UTP  in  the  atherosclerotic  veins184.  No 
comparison has been made  of purinergic  signalling between varicose  and healthy 
LSV.  It is also interesting to note that pharmacological  studies on the LSV have 
studied  the  circular  muscle;  none  have  studied  the  medial  longitudinal  smooth 
muscle present.
Analysis  of aortocoronary  LSV  grafts  showed  intimal  hyperplasia  results
from the migration and proliferation of de-differentiated SMC originating from the
media185  in response  to  mechanical  injury  and  haemodynamic  disturbances186,187.
Adenosine  is  known  to  inhibit  vascular  SMC  via  A2B   receptors.  Targeting  this
receptor may reduce the SMC hypertrophy seen in LSV grafts, thereby improving
its lifespan.  Studies of adenosine on vein grafts in the arterial circulation revealed 
188 unique properties
•  Vein graft adenosine-mediated relaxation is NO and prostanoid dependent.
•  A1-receptor activation in the vein graft produces an endothelium dependent 
contractile response, rather than an expected relaxant response.
•  A2-receptor mediated responses in the vein graft appear independent of the 
endothelium.
These  findings  suggest  the  vein  graft  has  neither  a  venous  nor  arterial 
phenotype.  ACh usually relaxes  vein  smooth muscle,  but  induces  contraction  in
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vein grafts, perhaps due to alteration of the muscarinic receptors.  Davies et al 
suggest that these findings are a result of functional changes of the EC, possibly a 
phenotype  change,  that  may  contribute  to  the  intimal  hyperplasia  seen  in  vein 
grafts.
49Purinergic signalling in skin
Purine receptor activity has been identified in skin epidermis.  A P2X3-like 
receptor is thought to reduce keratinocyte repair and mediate epidermal hyperplasia 
following injury189.  The roles of P2Xs, P2X7, P2Yi and P2Y2 receptors in different 
layers in human skin epidermis has been described previously190.  P2Yi  and P2Y2 
receptors  are  involved  in  keratinocyte  proliferation  in  the  stratum  basale,  while 
P2X5  receptors  are  associated  with  keratinocyte  differentiation  in  the  stratum 
basale, spinosum and granulosum and P2X7 receptors with keratinocyte cell death
1   190 191 in the stratum comeum  ’  .
Inoue  et  al192  identified  increased  levels  of P2X2,  P2X3,  P2X5  and  P2X7 
receptor  mRNA  in  differentiating  keratinocyte  cells.  mRNA  levels  of  P2Xj 
receptor fell whilst that of P2X4 remained unchanged during differentiation.  Burell 
et  al193  identified  mRNA  for  P2Y4,  and  P2Y6  receptors  on  keratinocytes  and 
concluded  that  P2Y4  receptors  played  a  regulatory  role  in  proliferation.  UTP 
stimulation of P2Y receptors leads to IL-6 production from keratinocytes194.
To  date,  the  role  of purine  receptors  on  keratinocytes  in  CVI  skin  and 
venous ulcer formation has not been reported.
Purinergic signalling in the penis
Penile  erection  involves  cholinergic,  adrenergic  and  purinergic 
pathways195.  Adenosine  has  been  shown  to  mediate  CSM  relaxation  via  A2A 
(pathway independent of NO) and A2B (partially endothelium dependent) receptor 
subtypes196'198.  Adenosine  also  induces  cavemosal peak blood flow velocity  and 
tumescence199’200.
ATP released neuronally or from endothelium, has been shown to induce 
CSM relaxation34,198,200'202.  ATP-mediated relaxation is more pronounced on CSM 
at high basal tension (when precontracted with phenylepherine)  .  At low CSM 
basal tension, ATP causes contraction.  It may be that ATP is involved as part of a 
regulatory mechanism  in maintaining physiological  CSM basal tone at rest.  ATP
50mediated  contractions  are  partially  attributable  to  its  metabolic  breakdown  to 
adenosine,  which acts directly on A2A  and A2B  receptor subtypes.  However P2Y 
receptor-mediated relaxation may be accountable too, leading to NO release from 
the endothelium  ’  .  The P2Yi  receptor has been identified on endothelial cells 
lining lacunar spaces but was  not identified on the  CSM in the rat  .  P2Yi  and 
P2Y2  receptors  have  been  identified  on  hamster  urethral  smooth  muscle  and 
relaxation to ATP is thought to be P2Yi receptor mediated207.  The role of the P2Y2 
receptor  may  be  to  mediate  trophic  effects,  as  it  is  known  to  mediate  the
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proliferation  of  keratinocytes  and  rat  aortic  smooth  muscle  cells  *   P2X 
receptors  induce contractions of CSM205.  Lee et al demonstrated the presence of 
strong P2Xi  and weaker P2X2 immunoreactivity in rat CSM, which suggests their 
possible involvement in the process of detumescence210.
51CHAPTER 2
Alterations In Purinoceptor Expression 
In Human Long Saphenous Vein 
During Chronic Venous Insufficiency
52Abstract
Varicose veins  are dilated tortuous veins of varying tone.  Purinergic  signalling is 
important in the control of tone and in mediating trophic changes in blood vessels. 
The  expression  of  P2  receptors  in  control  and  varicose  veins  was  examined. 
Purinergic signalling in circular and longitudinal smooth muscle of the human long 
saphenous  vein  was  studied  in  control  and  varicose  tissues  using 
immunohistochemistry,  organ bath pharmacology and electron microscopy.  P2Xi, 
P2Yi,  P2Y2,  P2Y4  and P2Y6  receptors  were  present  on circular  and  longitudinal 
smooth muscle. Purine-mediated circular and longitudinal muscle contractions were 
weaker in varicose veins. Electron microscopy and immunohistochemistry findings 
support the view that smooth muscle cells change from the contractile to synthetic 
phenotype  in  varicose  veins,  associated  with  an  upregulation  of P2Yi  and  P2Y2 
receptors  and  a  down  regulation  of P2Xi  receptors.  Down  regulation  of P2Xi 
receptors  on  the  smooth  muscle  of  varicose  veins  is  associated  with  loss  of 
contractile activity. Upregulation of P2Yi  and P2Y2 receptors is associated with a 
shift from contractile to synthetic and/or proliferative roles. The phenotype change 
in smooth muscle is associated with weakening of vein walls and may be a causal 
factor in the development of varicose veins.
53Introduction
As our life expectancy continues to increase along with our population size, 
the incidence of CVI is predicted to increase. Incompetent valves in varicose veins 
requiring  stripping  of  the  LSV  is  a  common  surgical  intervention  aimed  at 
inhibiting  disease  progression.  As  health  services  attempt  to  cut  costs,  stricter 
criteria exist for varicose vein surgery.  Cheaper alternatives for the management of 
CVI  are  an  attractive  welcome.  A  more  detailed  understanding  of the  disease 
process would help in the development of new treatments.
Structural  changes  between  healthy  and  varicose  LSV  have  been  well 
described  in  the  literature,  with  collagen  deposition  and  muscle  fibre 
disorganization  a  characteristic  feature26.  Contractile  strength  weakness  of the 
varicose circular smooth muscle is also reported24.  SMC are known to play a role 
in  the  pathophysiology  of  vascular  remodelling  that  occurs  in  hypertension, 
atherosclerosis  and  restenosis.  Their  roles  include  proliferation,  migration  and 
deposition of ECM eg collagen.  SMC show plasticity, changing from a contractile 
to a synthetic phenotype, which is central to these processes127.
Purinergic  signalling has been demonstrated in the  LSV179,180 as discussed 
earlier, with one  study comparing purine-mediated contractions  on varicose veins 
with veins obtained from atherosclerotic legs184. No comparison has been made of 
its role between varicose and healthy LSV.  Aside from the  short term  actions of 
purines on blood vessels, purines have long term proliferative actions too125.
This study was aimed at examining the expression of different P2 receptor 
subtypes present in healthy and varicose human LSV and comparing the contractile 
effects mediated by these receptors in both circular and longitudinal smooth muscle. 
Vein wall ultrastructure, with particular emphasis on smooth muscle phenotype was 
also studied.
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Patients
Proximal  end varicose  vein  segments  were  obtained  from  31  patients  (19 
female,  12 male, aged 21-77, mean age 46.8 ± 2.6 years) undergoing stripping of 
their LSV. The most proximal end of the sample was obtained prior to insertion of 
the  stripper.  Reflux, had  been  confirmed  by  either  hand  held  doppler  or  venous 
duplex  scanning by the  vascular team  prior to  surgery.  Healthy  control  vein was 
obtained  from  34  patients  (6  female,  28  male,  aged  41-84,  mean  age  63.6  ±1.6 
years) undergoing coronary artery bypass surgery where the LSV was harvested for 
a graft. A segment from the proximal end of the exposed LSV was excised for the 
study  prior  to  distension.  Reflux  was  excluded  in  control  patients  by  hand  held 
doppler prior to  surgery.  Diabetic  patients  were  excluded  from  the  study.  Ethics 
approval  was  obtained  by  the  joint  UCL/ULCH  Ethics  Committees  on  Human 
Research and by the Royal Free Hampstead Research Ethics Committee.
Immunohistochemistry
Vein  segments  were  collected  in  Hanks  balanced  salt  solution  (HBSS; 
Invitrogen,  Paisley,  UK)  and  frozen  in  isopentane,  precooled  in  liquid  nitrogen. 
Segments were sectioned at 10pm on a cryostat (Reichert Jung CM 1800), collected 
on gelatine-coated slides and air dried at room temperature. Slides were stored at - 
20°C.  Sections were fixed for 4 min in 4% formaldehyde in 0.1 M phosphate buffer 
solution (PBS) containing 0.2% picric acid, then washed three times for 5 min with 
PBS.  Sections  were  primarily  blocked  for  60  min  in  10%  normal  horse  serum 
(NHS)  in  0.1M  phosphate  buffer,  containing  0.05%  merthiolate.  Sections  were 
incubated overnight with two primary antibodies: polyclonal P2X (P2Xi-6) (Roche 
Palo  Alto,  CA,  USA)  or  P2Y  (P2Yj,  P2Y2,  P2Y4,  P2Y6,  P2Yn)  (Alomone
55Laboratories, Jerusalem, Israel) antibodies at concentrations of 1:50 to  1:200,  and 
monoclonal anti a-smooth muscle actin antibody (Sigma Chemical Co., Poole, UK) 
at  1:400 in 10% NHS in PBS with 0.05% merthiolate. On the second day, sections 
were  washed  three  times  for  5  min  in PBS  and  then  stained  with the  secondary 
antibodies:  donkey  anti-rabbit  Cy3  (Jackson  Immunoresearch  Laboratories,  West 
Grove,  USA)  at  1:300  and  donkey  anti-mouse  FITC  (Jackson)  at  1:200  in PBS- 
merthiolate for 60 min.  Sections were washed three times for 5 min before being 
mounted  in  Citifluor  (Citifluor  Ltd,  London,  UK).  Control  experiments  were 
performed by omitting the primary and  secondary antibody,  and by preabsorbing 
the primary antibody with its corresponding peptide. Preabsorption was carried out 
by adding the peptide at a ratio of 1:1  in 10% NHS in PBS with 0.05% merthiolate, 
leaving  for  12 hours at 4°C, passing through a syringe  filter (4mm with a 0.2pm 
PPmembrane) then centrifuged at 13,000rpms for 5 min using only the supernatant.
Semi-quantitative assessment of the changes in immunofluorescent intensity 
was performed by an independent observer,  blinded  from  the patient  group  from 
which samples were taken.
Haematoxylin  and  Eosin  (H&E)  slides  were  prepared  by  fixing  in  4% 
paraformaldehyde in PBS for 10 min. Sections were washed in distilled water then 
stained  for 20  min  in  Ehrlichs  Haematoxylin.  Following  washing  in  running  tap 
water,  slides were dipped in acid alcohol  and washed again for  15  min.  Sections 
were then stained in Eosin for 5 min, dipped in tap water, then washed for 1  min in 
70% alcohol, 3 min 100% alcohol, another 3 min 100% alcohol, dried for 3 min in 
xylene, and finally another 5 min in xylene. Sections were mounted in eukitt.
The results were photographed using a Zeiss Axioplan, high definition light 
microscope  (Zeiss,  Oberkocken,  Germany) mounted with a Leica DC  200  digital 
camera (Leica, Heerbrugg, Switzerland).
56Electron microscopy
For  electron  microscopy  vein  segments  were  collected  in  HBSS  and 
transported  back  to  the  laboratory  and  fixed  in  2%  paraformaldehyde,  2% 
glutaraldehyde in 0.1 M phosphate solution. Tissue was washed in phosphate buffer, 
post-fixed in 1% osmium tetroxide in phosphate buffer, en-block stained with a 2% 
solution  of uranyl  acetate  in  distilled  water,  dehydrated  in  graded  ethanols  and 
embedded  in  an  agar  resin.  80nm  thick  sections  were  cut  and  collected  on  thin 
films, counterstained with lead citrate and viewed in a Jeol 1010 TEM.
Pharmacology
For  functional  pharmacology  experiments  tissues  were  collected  in  Krebs 
solution (pH 7.2) of the following composition (mM): NaCl 133, KC14.7, NaH2PC> 4  
1.35, NaHCC> 3 16.3, MgSC> 4 0.61, CaCh 2.52 and glucose 7.8. Tissues were cleaned 
of adherent connective tissue and set up in  10ml organ baths containing the above 
Krebs solution, gassed with 95% 02-5% CO2, and maintained at 37±1°C within 2 
hours of collection.
Circular muscle was tested by  cutting ring vein  segments  of 5mm  length, 
mounted with tungsten wires to an L-shaped stainless steel rod.  Isometric tension 
was  recorded  with  a  Grass  FT03C  force-displacement  transducer.  Rings  were 
placed under an initial tension of 2g and allowed to equilibrate for 60mins prior to 
experiments  starting.  Longitudinal  muscle  was  tested  on  15mm  lengths  of vein, 
suspended  with  silk  thread,  between  an  L-shaped  rod  and  a  Grass  FT03C 
transducer.  A  resting  tension  of 2.5g  was  applied  and  allowed  to  equilibrate  for 
60min  prior  to  isometric  tension  recordings.  Mechanical  activity  was  recorded 
using  the  software  PowerLab  Chart  for  Windows  (version  4;  ADInstruments, 
Australia).  Contractions  along the  longitudinal  axis (along the  length of the vein) 
were measured, which recorded activity of both the longitudinal smooth muscle and 
the longitudinal component of disorganised fibres.
57NA  was  applied  accumulatively  to  the  organ  baths  at  increasing 
concentrations  (10'8 to  10'3  M).  Baths were then washed and the vein allowed to 
return to  its resting tension. Not all vein segments were  exposed to the complete 
range of concentrations, some segments received a one off concentration (10* 5 M), 
were washed, and tension readings obtained for the remaining experiments. This did 
not significantly affect later results. ATP was applied non-cumulatively (10'6 to 10'3 
M) separated by 15 min intervals, washing in between. After a further 30 min rest,
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a,p-meATP  (10'  to  10'  M) was added in the  same manner.  Vein segments were 
again  washed  and  upon  returning  to  their  resting  tension  (approx  30min)  were 
contracted to increasing concentrations of KC1 (10'5 to 3x1 O '1  M).
On separate vein segments the effect of one of the following P2Y agonists 
was  examined.  2-MeSADP  (10'8  to  10'5  M)  was  applied  cumulatively  and  a 
concentration-response curve was constructed.  Following wash-out, the curve was 
repeated in the presence of the antagonist MRS2179 (10'6 M).  On a separate vein 
segment, a concentration-response curve was constructed to UDP (10'6 to  10'3 M); 
this  was  repeated  in the  presence  of the  antagonist  cibacron blue  3GA  (10'4 M). 
Finally, a concentration-response curve was constructed to UTP (10'6to 10'3 M) and 
repeated in the presence  of the antagonist suramin (10'4 M).  All  antagonists were 
incubated for 45mins prior to the addition of the agonist.
With the exception of NA, full concentration-response curves could not be 
constructed since the maximum concentration of agonist that could be applied to the 
organ bath was less than that required to obtain a maximum contraction.
Electrical  field response  of longitudinal  muscle  was tested using platinum 
wire electrodes, one placed in the lumen and one outside of the vessel. Transmural 
nerve stimulation was delivered for lmin by an electronic stimulator (Grass SD9) at 
1-16Hz (100V, 0.1ms duration) with rest periods of 10-20min. Frequency response 
curves were repeated firstly in the presence of an adrenergic antagonist  (prazosin 
10'6  M),  then  in  the  presence  of both  prazosin  and  the  purinoceptor  antagonist 
PPADS  (3x10'5 M)  and  finally  in  the  presence  of the  nerve  conduction  blocker 
tetrodotoxin  (TTX;  10'6M).  All  agonists  were  allowed  to  equilibrate  for  30mins 
before stimulation commenced.
58The  integrity  of the  endothelium  was  examined  in  control  and  varicosed 
samples by their ability to relax to ACh. Vessels were precontracted with NA (EC50 
concentration) and increasing concentrations of ACh were applied (10'7 -  10'3M).
Statistical Analysis
All  concentration-response  curves  were  expressed  as  -log  of the  molar 
concentration of the agonist.  Concentration-response curves to NA were prepared 
using the software Prism 3.0 (GraphPad Software, Inc., San Diego, CA, USA). For 
each curve the software  calculates the lower and upper plateau, the  slope and the 
EC50 value ±SE of the mean by means of a linear regression analysis. Significance 
for  all  concentration  response  curves  was  tested  using  a  two-way  analysis  of 
variance  (ANOVA) followed by a post hoc test  (Bonferroni’s).  A probability of 
PO.05 was taken as significant.
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An un-paired two-tailed /-test revealed a significant age difference between 
the two groups (PO.OOOl), the control group being older.
Histology
Sections  stained  with  H&E  confirmed  previously  published  findings  of 
smooth  muscle  variation  in  varicose  sections  between  atrophic  and  hypertrophic 
segments26.  Atrophic  sections  consisted  of  reduced  ECM  and  SMC  content 
resulting in a thin vein wall where individual layers could not be distinguished. In 
hypertrophic  segments  an  increase  in  extracellular  matrix  broke  up  the  smooth 
muscle bundles. The intima was often thickened with hyperplasia and hypertrophy 
of the longitudinal SMC, consistent with the earlier report by Wali et al211.
Using an antibody to smooth muscle actin, our double staining fluorescent 
immunohistochemistry identified P2Xi, P2Yi, P2Y2, P2Y4 and P2Y6 receptors on 
longitudinal and circular smooth muscle. There was no immunostaining for P2X2-6 
or P2Yn receptors.  There was a reduction in intensity of the P2Xi receptor staining 
in the varicose vein sections (Fig.  2.1b) when compared to the control vein (Fig. 
2.1a). Conversely, there was an increase in intensity of the P2Yj receptor staining in 
the  varicose  sections  (Fig.  2.2b)  when  compared  to  the  control  vein  (Fig.  2.2a). 
P2Y2 receptor staining (Fig. 2.3a and 2.3b) was weak in both tissue groups, but its 
intensity was increased on intimal longitudinal muscle in most of the varicose veins. 
P2Y4  (Fig.  2.4a  and  2.4b)  and  P2Y6  (Fig.  2.5a  and  2.5b)  receptors  stained  with 
similar  intensities  in  control  and  varicose  sections.  Preabsorption  of the  primary 
purinoceptor  antibody  with  its  corresponding  peptide  showed  reduced 
immunofluorescence for all receptors in both control and varicose vein (Fig. 2.1c, 
2.Id, 2.2c, 2.2d, 2.3c, 2.3d, 2.4c, 2.4d, 2.5c and 2.5d).  For each P2 receptor, control 
and  varicose  tissue  from  a  minimum  of  10  patients  each  were 
immunostained and compared.
60Colocalisation  of purinoceptor  and  smooth  muscle  actin  staining  of the 
boxed  areas  in  figure  2.1a  and  2.2b  are  represented  in  figures  2.6  and  2.7  at 
increased magnification.  The red P2Xi  staining (Fig.  2.6a) and the  green smooth 
muscle actin staining (Fig. 2.6b) on the same section are shown. When the images 
are  overlapped,  the  smooth  muscle  cells  that  contain  actin  and  P2Xj  receptors 
appear yellow (Fig 2.6c), confirming the location of the purinoceptor on the SMC. 
Similar findings are shown for P2Yi, confirming the presence of the purinoceptor 
on the SMC (Fig. 2.7a, 2.7b and 2.7c).
Electron Microscopy
At  high  magnification,  structures  could  be  identified  in  healthy  (control) 
veins  that  are  characteristic  of  a  smooth  muscle  contractile  phenotype.  These 
include  numerous myofilaments that attach to  dense  bodies  within the cytoplasm 
and in dense areas of the plasma membrane that alternate with caveolae. Organelles 
(including mitochondria and golgi complexes) are located in the perinuclear region 
(Fig. 2.8a). SMC were tightly packed together in organised bundles and surrounded 
by fibrous tissue (Fig. 2.9a).
High  magnification  of  varicose  SMC  revealed  properties  that  are 
characteristic  of  a  synthetic  phenotype.  Whilst  some  varicose  SMC  showed 
characteristics  similar to  that  of control  SMC,  other varicose  SMC  contained  an 
increased volume of organelles (including vesicles and dilated rough endoplasmic 
reticulum)  and these  were  located  at the  periphery  of the  cell  (Fig.  2.8b).  These 
cells, though synthetic in their appearance, were confirmed as being a SMC by the 
presence of a continuous basal  lamina with caveolae  and a limited appearance of 
myofilaments  and  dense  bodies.  The  varicose  SMC  showing  synthetic  properties 
were located around the intimal and inner medial layers.  Due to the disorganisation 
of muscle fibres seen in varicose veins, it was not possible to distinguish whether 
they were longitudinal or circular fibres. No synthetic phenotyped SMC was seen in 
the adventitia.  Low magnification of the varicose sections revealed an increase in
61collagen and elastic tissue separating the muscle bundles, when compared to control 
sections (Fig. 2.9b).
Functional Experiments on Circular Smooth Muscle
The LSV circular muscle contracted to NA and KC1, and contractions were reduced 
in the varicose tissue (PO.OOOl  and P=0.0338, respectively) (Fig. 2.10a). Circular 
muscle contracted to both P2Xi receptor agonists; contractions to ATP (P=0.0178) 
and a,p-meATP (P=0.0292) (Fig. 2.10b) were significantly reduced in the varicose 
tissue.
ACh failed to induce relaxation on NA (EC50 concentration) precontracted 
control or varicose vessels.  At times, contractions were seen instead.  This suggests 
that the endothelium in the two vessel groups was significantly disrupted (figure not 
shown).  ACh  caused  small  contractions  instead  due  to  its  muscarinic  actions 
directly on the smooth muscle cells.
Functional Experiments on Longitudinal Smooth Muscle
Longitudinal muscle  in both healthy and varicose vein contracted to purinoceptor 
and adrenoceptor agonists. There was a significant reduction in contractions of the 
varicose  tissue  to  NA  (PO.OOOl),  KC1  (PO.0324),  ATP  (PO.OOOl)  and  a,p- 
meATP (P0.0033) (Fig. 2.10c and 2.10d).
Unlike circular muscle, the  longitudinal muscle  contracted to  several  P2Y 
receptor agonists. Significant reductions in contractions were again seen in varicose 
tissue to 2-MeSADP (P0.0091), UTP (PO.0369) and UDP (PO.292) (Fig. 2.1 la, 
2.1 lb and 2.1 lc) compared to control tissue.
In  both  control  and  varicose  tissue,  contractions  to  2-MeSADP  were 
significantly reduced (PO.OOOl  and PO.0125, respectively) in the presence of the 
competitive  P2Yi  receptor  antagonist  MRS2179  (10'6M).  Contractions  to  UDP
62were  also  significantly reduced in the presence  of the  non selective P2 receptor 
antagonist cibacron blue 3GA (lO^M) (varicose tissue, PO.OOOl and control tissue, 
P=0.0008)  (Fig.  2.lid   and  2.1 le).  Contractions  to  UTP  were  inhibited  with 
suramin (10'4M). UTP is an agonist at both P2Y2 and P2Y4 receptors, however the 
antagonist  suramin  enables  a  distinction  to  be  made  between  suramin-sensitive 
P2Y2  and  suramin-insensitive  P2Y4  receptors212.  Significant  reductions  in 
longitudinal  muscle  contraction  in  control  (P=0.0009)  and  varicose  (P=0.0023) 
tissue were seen in its presence.
As  with  circular  muscle,  ACh  failed  to  induce  relaxation  on  NA  (EC50 
concentration) precontracted control or varicose veins.  At times, contractions were 
seen instead (Fig 2.12).  This suggests that the endothelium in the two vessel groups 
was significantly disrupted. ACh caused small contractions instead due to its post 
ganglionic parasympathetic muscarinic actions directly on the smooth muscle cells.
Electrical  field  stimulation  induced  frequency-dependent  increases  in 
tension  in  longitudinal  muscle.  The  addition  of  prazosin  significantly  reduced 
contractility  (P<0.0001)  and  the  subsequent  addition  of  PPADS  reduced 
contractility even further (P=0.0481)  (Fig.  2.Ilf).  Frequency  response  curves, 
without the addition of any antagonists, acted as time controls demonstrating 
no  smooth muscle  fatigue.  Increasing the  stimulation frequency results  in 
greater receptor activation and an increase in receptor effects.  Our results 
demonstrate  that  longitudinal  muscle  contractions  consist  of  both 
noradrenaline  and  purine-mediated  responses.  The  addition  of  TTX 
produced  a  graph  similar  to  that  of  PPADS  and  prazosin  combined, 
indicating  that  all  responses  were  due  to  nerve  mediated  stimulation. 
Residual responses with TTX represent direct muscle stimulation.
Contractions to UTP were thought to be P2Y2 receptor mediated due 
to  the  significant  contraction  reduction  seen  with  the  addition  of  the 
antagonist suramin.  Contractions to UTP, in the presence of suramin, could 
be P2Y4 receptor mediated, but as they were small and due to the lack of 
specific P2Y4 receptor antagonists, this was not further investigated.
63Discussion
There was a significant age difference between the control and varicose vein 
groups.  There  was  also  a  greater  proportion  of females  in  the  varicose  group. 
Oestrogen has been considered to be a causal  factor of varicose veins  , perhaps 
explaining the increased prevalence amongst females.  During pregnancy, varicose 
vein presentation increases along with plasma oestrogen levels. Post partum, when 
oestrogen  levels  fall,  varicose  veins  commonly  resolve.  However  other  factors 
during pregnancy must not be ignored, such as the enlarged uterus impairing venous 
drainage from the lower limbs. Oestrogen is thought to affect vascular wall strength 
by relaxing smooth muscle and softening collagen fibres. Oestrogen receptors have 
been  identified  on  varicose  and  control  LSV214.  Oestrogen  not  only  affects  the 
smooth muscle in vessel walls, but also affects the collagen in regulating the wall 
strength. Haynes et al215 showed that oestrogen increases P2Xi  and P2X7 receptor- 
mediated  contractions  in  uterine  arteries.  Further,  UTP  was  shown  to  be  more 
potent in oestradiol-treated animals (low progesterone levels), and an upregulation 
of a UTP-specific pyrimidine receptor subtype was thought to occur, although no 
differences were seen in pregnant animals.
The findings of competent valves in patients with a 20 year history of gross 
varicosities23 and of the presence of varicosities below competent valves, supports 
the theory of vein wall weakness and is contradictory to that of valve insufficiency. 
A  saphena varix,  where  a  saccular  dilatation  occurs  laterally  out  of normal  vein 
wall, suggests a localised weakness that progresses. If back pressure was the source, 
then the whole wall would be expected to be evenly affected. When a muscular tube 
sustains  damage  due  to  chronic  pressure,  it  responds  with  hypertrophy  (eg  LSV 
hypertrophies at arterial pressures in bypass surgery). Exposed to increased chronic 
venous pressure the LSV could be expected to hypertrophy rather than respond by 
passive dilatation, suggesting an underlying vein wall weakness.
Hypertrophy  of the  intimal  longitudinal  muscle  layer  in varicose  veins  is 
consistent with previous studies29. An increase in cell size with no changes in cell 
number,  suggesting  hypertrophy  but  not  hyperplasia  has  been  reported  in
64916
hypertensive rat portal vein  . Theories for the intimal changes include hypoxia of 
the  endothelial  cells217,218 and  endothelium  disruption  causing  SMC  exposure  to 
blood  flow  leading  to  modulation  of  its  function219,220.  The  possibility  of 
modulating  the  SMC  function  by  an  increase  of  the  extracellular  matrix  was 
suggested  by  Lee  et  al221,  and  is  supported  by  the  increase  in  SMC  and  ECM 
(collagen) in the LSV222. It has been previously proposed that varicose changes are
90
not due to vein wall deficiencies but rather to modulation of their normal function  . 
The separation of the SMC by increased ECM in the hypertrophic intima suggests 
they  have  proliferative  and  synthetic  functions  and  have  adopted  a  different
96
phenotype  .  Analysis  of  aortocoronary  saphenous  vein  grafts  showed  intimal 
hyperplasia results from the migration and proliferation of de-differentiated SMCs 
originating  from  the  media  in  response  to  mechanical  injury  and  haemodynamic
96
disturbances  .  A  similar  physiological  exposure  occurs  in  the  LSV  due  to  the 
increased  venous  pressure.  This  could  promote  the  SMC  to  change  phenotype.
99^
Bujan et al  studied elastin expression in LSV and their findings indicated a higher 
metabolism  of  the  elastic  component  in  varicose  veins.  They  concluded  that 
varicose  pathology  involved  a  restructuring  of the  elastic  component  of the  vein 
wall, which could be a consequence of alterations in the transcription mechanisms 
of muscle cells.
The  electron  microscopy  findings  in  control  veins  were  characteristic  of 
contractile SMC as previously reported28. Populations of poorly differentiated SMC 
with  an  increase  in  secretory  cytoplasmic  organelles  and  a reduction  in  filament 
bundles,  characteristics  seen in synthetic phenotyped  SMC,  have been previously 
noted  in LSV used  in  surgery  for critical  ischaemia,  where  no  history of venous
90
disease  was  given  but  tests  to  exclude  varicose  veins  were  not  performed  . 
Phagocytic and secretory properties of SMC in varicose vein have been previously
9^911
suggested  ’  . The ECM seen in varicose veins could be synthesised via synthetic 
phenotyped SMC.
In  the  varicose  vein  wall,  a  significant  increase  in  transforming  growth 
factor pi  (which stimulates the synthesis of ECM components, especially collagens 
and  elastin,  reduces  the  expression  of  matrix  metalloproteinases  and  increases
65expression  of tissue  inhibitors)  and  an  increase  in  the  cytokine  basic  fibroblast 
growth factor (known to be chemotactic and mitogenic for SMC) has been reported, 
with no variation in vascular endothelial growth factor26. Inflammatory cells could 
not  account  for  the  cytokine  modulation  as  they  were  not  present.  These  three 
mechanisms could increase the ECM in varicose veins.
Previous  studies  on  animal  and  human  LSV  have  shown  reduced 
contractility to angiotensin II, NA, endothelin-1  and KC1 of the circular muscle in 
the varicose  state24,224.  P2Xj,  P2Y2, P2Y6 receptors have been identified on the
170  1  ft 1   1  ft2
circular smooth muscle in previous studies  '  *   , however for the first time we 
show a reduction in contractility through P2Xi receptors in the varicose tissue. Our 
findings of reduced contractions to NA and KC1 in varicose tissue is consistent with 
those of others24,224. Reduced contractions may result from a combination of both 
decreased muscle volume and weaker contractile muscle cells in the varicose vein.
For the first time we have recorded contractions of the longitudinal smooth 
muscle on the human LSV,  showing contractions mediated by P2Xi, P2Yi, P2Y2 
and P2Y6 receptors. mRNA of P2Yi  receptors has been detected on endothelium- 
denuded healthy LSV181 and on LSV endothelial cells182, but no contractile property 
has been demonstrated. P2Yi receptors on endothelial cells mediate vasodilatation, 
but  for  the  first  time  we  have  shown  stimulation  of  P2Yi  receptors  induces 
contraction  of the  longitudinal  muscle.  Our  results  also  show  that  longitudinal 
muscle  contractions  to  both  adrenoceptors  and  purinoceptors  are  reduced  in 
varicose tissue.
ACh  is  known  to  cause  vasodilatation  by  stimulation  of the  muscarinic 
receptors located on endothelial cells, triggering a release of NO, initially known as 
‘endothelium-dependent  relaxing  factor’  (EDRF).  In our experiments  it failed to 
cause  relaxation,  suggesting  that  EC  had  been  damaged  during  the  tissue 
preparation.  At higher ACh concentrations, vasoconstriction was noted, a result of 
the  direct  actions  of ACh  on  muscarinic  receptors on smooth muscle.
Whilst we did not actively denude endothelial cells from the vein preparations, they 
were inactive when it came to our functional experiments.  Endothelium-mediated 
relaxation of vein wall tone did not interfere with our experimental results.
66Contractile properties of longitudinal muscle in both the media and intima of 
the human internal coronary artery225 has been previously demonstrated.  In the rat 
portal vein, functional studies demonstrated P2X receptor-mediated contractions of 
longitudinal muscle226,227 and histological studies showed that in hypertension, the 
outer longitudinal muscle cells have an irregular outline and hypertrophy228. Similar 
histological  results  have  been  seen  in  hypertensive  rat  arteries229.  LSV  has  both 
intimal  and  outer  medial  longitudinal  muscle  bundles,  and  we  have  shown  their 
combined  purinergic  and  adrenergic  contractile  properties.  We  were  unable  to 
separate the two layers as they are often difficult to identify in the varicose tissue.
SMC and endothelial cell proliferation, death and secretory properties play 
important  roles  in  both  new  vessel  growth  during  wound  healing  and  intimal 
thickening  during  arterial  diseases124,125.  Purinoceptors,  aside  from  their  role  in 
vessel tone control, are known to play important roles in the signalling pathways of 
these  events103,127.  Selective  agonists  have  shown the  contractile  effects  in  blood 
vessels are mediated mainly by P2Xi receptors with smaller effects by P2Y2, P2Y4 
and  P2Y6  receptors60,230,  while  the  mitogenic  effects  of smooth  muscle  cells  are 
mediated  by  P2Yi,  P2Y2,  P2Y4  and  P2Y6  receptors60,127.  The  transition  from 
contractile  to  synthetic  SMC  phenotypes  has  been  shown  in  atherosclerosis, 
restenosis after angioplasty and during cell culture  in vitro127>231.  mRNA levels of 
P2Y1   and P2Y2 receptors increase 342-fold and 8-fold, respectively, in cultured rat 
aortic  smooth muscle  cells that  show the  synthetic  phenotype  when compared to 
phenotypic contractile cells in freshly dissociated muscle100.  P2Xi receptor mRNA, 
present  in  the  contractile  cells,  was  not  detected  in  the  synthetic  cells.  mRNA 
levels of P2Y4 and P2Y6 receptors were similar in both cell phenotypes.  P2Y4 and 
P2Y6 receptor activation stimulates mitogenesis in SMC102,232. The smooth muscle 
cells  in  varicose  LSV  show  similar  changes  in  expression,  ie.  reduced  P2Xi 
receptor  immunostaining  and  reduced  P2Xi-mediated  contraction.  There  is  also 
increased  immunostaining  intensity  of P2Y1   and  P2Y2  receptors,  associated with 
increased  synthetic  and  proliferative  activity,  and  loss  of  contractile  activity. 
Immunostaining intensity remained constant for P2Y4 and P2Y6 receptors, although 
there was a reduction in P2Y6-mediated contractions in varicose veins.
67Activation  of  endothelial  cell  production  of  nitric  oxide  and  increased 
sensitivity of the smooth muscle is thought to lead to increased synthesis of cyclic 
GMP and heighten vascular relaxation233. A mitogenic phenotype may account for 
this  altered  sensitivity.  In aortic  SMC,  A2B   receptor activation  inhibits  growth234, 
and  either  P2Y2  or  P2Y4  receptor  activation  stimulates  cell  proliferation129.  In 
atherosclerosis there  is  an upregulation of P2Y2 receptors  by a mitogen-activated 
protein kinase (MAPK)-dependent growth factor.  Suramin inhibits platelet derived 
growth  factor  (PDGF)  receptor  activation  and  signalling  through  the  MAPK- 
activator protein  1   pathway.  PDGF  is  a  growth  factor  antagonist  inhibiting  cell
1
proliferation and reducing neointimal thickness in LSV grafts in mice  . These two 
findings suggest an increased P2Y2 receptor expression in a hypertrophied intima, 
similar to our theory of increased P2Y2 receptor expression in varicose intima.
Intimal  longitudinal  smooth  muscle  is  more  prominent  in  hypertrophied 
varicose  vein  segments.  It  is  visible  in  Figure2.9b,but  is  more  clearly  visible  in 
Figure 2.2b. P2Yi and P2Y2 receptors stain to a bright intensity on the intimal muscle 
in  varicose  sections.  However  due  to  the  disorganisation  of muscle  bundles  in 
varicose tissue, longitudinal and circular muscles are not always clearly identifiable. 
We have contracted, for the first time, intimal and outer medial longitudinal muscle 
together in LSV. We propose that intimal longitudinal smooth muscle undergoes a 
change from contractile to synthetic phenotype in varicose veins. This is supported 
by  the  increase  in  intimal  smooth  muscle  volume,  a  reduction  in  its  contractile 
strength,  increases  in  intimal  extracellular  matrix,  increased  intensity  of intimal 
P2Yj and P2Y2 receptor staining and reduced intimal P2Xj receptor staining.
What is the source of the ATP that acts on the P2 receptors expressed on the 
smooth muscle of LSV? One possibility is that ATP is released as a cotransmitter 
with NA from perivascular sympathetic nerves  . Another is that ATP is released
0 0
from endothelial cells during changes in flow (shear stress) and hypoxia  . A further 
question  that  will  need to  be  resolved  is  whether the  changes  in  smooth  muscle 
phenotype  and  associated  changes  in  purinergic  signalling  are  causal  or 
consequential in varicose vein development.
68An  understanding  of  these  changes  occurring  within  the  purinergic 
signalling pathway may identify targets for therapeutic intervention. Modulation of 
vein muscle phenotype  may be  a useful  approach for treating varicose  veins  and 
subsequent chronic venous  insufficiency.  It could potentially optimise the role  of 
the long saphenous vein as a bypass graft.
69Figure  2.1:  Immunofluorescent  staining  of transverse  sections  of LSV.  P2Xi 
receptors  on control  (a)  and varicose  (b)  veins.  Reduced  immunofluorescence  is 
seen when the antibody  is blocked with its peptide  in  control (c) and varicose (d) 
veins  for P2Xi  receptors.  (L  =  lumen,  I  =  intima,  M  =  media,  A  =  adventitia). 
Boxed areas in (a) represent areas magnified in Fig 2.6 (a, b and c).
Control  Varicose
(b)
•if'  i  .
V ' :-
M
L
A
lOOum
(c)
1  OOum
(d)
OOum
70Figure  2.2:  Immunofluorescent  staining  of transverse  sections  of  LSV.  P2Yi 
receptors  on  control  (a)  and varicose  (b)  veins.  Reduced  immunofluorescence  is 
seen when the  antibody  is blocked with its peptide in control (c) and varicose (d) 
veins  for P2Yi  receptors.  (L  =  lumen,  I  =  intima,  M  =  media,  A  =  adventitia). 
Boxed areas in (b) represent areas magnified in Fig 2.7 (a, b and c).
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71Figure  2.3:  Immunofluorescent  staining  of transverse  sections  of LSV.  P2Y2 
receptors  on control  (a)  and varicose  (b)  veins.  Reduced  immunofluorescence  is 
seen when the  antibody  is blocked with its peptide in control (c) and varicose (d) 
veins for P2Y2 receptors.  (L = lumen, I = intima, M = media, A = adventitia)
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72Figure  2.4:  Immunofluorescent  staining  of transverse  sections  of  LSV.  P2Y4 
receptors  on  control  (a)  and varicose  (b)  veins.  Reduced  immunofluorescence  is 
seen when the antibody is blocked with its peptide  in control (c) and varicose (d) 
veins for P2Y4 receptors.  (L = lumen, I = intima, M = media, A = adventitia)
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73Figure  2.5:  Immunofluorescent  staining  of transverse  sections  of LSV.  P2Y6 
receptors  on control  (a)  and varicose  (b) veins.  Reduced  immunofluorescence  is 
seen when the antibody is blocked with the P2Y6 peptide in control (c) and varicose 
(d) veins.  (L = lumen, I = intima, M = media, A = adventitia)
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74Figure 2.6:  Immunostaining of the transverse sections of LSV, outlined by the box 
in Fig 2.1(a).  Red immunostaining of the P2Xj  receptor in control vein (a).  The 
same section simultaneously stained green for smooth muscle actin (b).  Combining 
both images for each section shows the colocalisation (yellow/orange) of P2Xi and 
actin on SMC (c).
75Figure 2.6Figure 2.7: Immunostaining of the transverse sections of LSV, outlined by the box 
in Fig 2.1(a).  Red immunostaining of the P2Yi receptor in varicose vein (a).  The 
same section simultaneously stained green for smooth muscle actin (b).  Combining 
both images for each section shows the colocalisation (yellow/orange) of P2Y i and 
actin on SMC (c).
77Figure 2.7 (a)
78Figure 2.8:  Electron microscopy of SMC demonstrating the contractile phenotype 
in  control  veins  (a)  and  the  synthetic  phenotype  found  in  varicose  veins  (b). 
Organelles  appear perinuclear  in the  contractile  phenotype,  and towards  the  cell 
periphery in the synthetic phenotype. (Cav = caveolae, RER = rough endoplasmic 
reticulum, DB = dense bodies).
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(a)  Contractile phenotype  (b)  Synthetic phenotypeFigure  2.9:  Electron microscopy  of longitudinal  sections  of LSV  comparing the 
closely bound muscle bundles in control vein (a) with the SMC that are separated 
by an increase in the extracellular matrix in varicose vein (b). (ECM = extracellular 
matrix, long = intimal longitudinal muscle, circ = circular muscle).
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(a)  Control Vein  (b)  Varicose VeinFigure 2.10
Concentration-response curves of circular (a, b) and longitudinal (c, d) smooth 
muscle of control and varicose human LSV.  NA (10'8 to 10'3 M) and KC1 (10'5 to 
3x1 O’1  M) contractions (a,c), and a,p-meATP (10-8 to 10'5 M)  and ATP (10'6 to 10'3 
M) contractions  (b,d) are shown. All symbols represent mean ± SE (unless masked 
by the symbol).
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83Figure 2.11
Concentration response-curves of control and varicose longitudinal smooth muscle 
from LSV to P2 receptor agonists, and in the absence and presence of P2 receptor 
antagonists, (a) 2MeSADP (10'8 to 10'5 M); (b) UTP (10'6 to 10'3 M); (c) UDP (10‘6 
to  10'3 M). Concentration response curves to the P2Y6 receptor agonist UDP (10'6 
to 10'3 M) in the absence and presence of cibacron blue 3GA (10* 4 M) in control (d) 
and varicose (e) LSV. (f) Electrical field stimulation of longitudinal smooth muscle 
in  control  LSV  in  the  absence  and  presence  of prazosin  (10'6  M),  then  in  the 
presence  of prazosin  and  PPADS  (3xlO'5M).  All  symbols  represent  mean  ±  SE 
(unless masked by symbol).
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85Figure  2.12:  Graph  of tracing  of longitudinal  smooth  muscle  tension  following 
contraction  with  NA  (EC50  concentration)  and  subsequent  contractions  with 
cumulative doses of ACh. (a) NA EC50 concentration, (b) ACh  1  O’7, (c) ACh  1  O’6,
(d)AChlO’5,  (e)AChlO-4.
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86Chapter 3
Purinoceptor Expression On Keratinocvtes 
Reflects Their Function 
On The Epidermis During 
Chronic Venous Insufficiency
87Abstract
Purines  are  extracellular  nucleotides  that  have  long  term  effects  on 
keratinocyte proliferation, differentiation and death through P2Yi, P2Y2, P2Xs and 
P2X7 receptors. This study examined changes in expression of these P2 receptors on 
lower  leg  epidermal  keratinocytes  in  control  and  chronic  venous  insufficiency 
(CVI) states. Lower limb skin biopsies from CVI (CEAP classification 4a and 4b) 
and  control  skin  were  immunostained  for  the  above  P2  receptor  subtypes  and 
epidermal area was calculated. Our results with CVI show an increase in P2Y1  and 
P2Y2  receptor  expression  in  basal  and  spinosal  layers  of the  epidermis  and  an 
increase of P2Xs receptors mainly in the spinosal layer and extending further into 
the  stratum  granulosum.  In  contrast  P2X7  receptors  were  reduced  in  the  stratum 
comeum in CVI. In conclusion, a thinner epidermis was found in CVI, which might 
be  the  result  of  the  changes  in  expression  of  P2Y  and  P2X  receptors  on 
keratinocytes:  that  is,  increased  proliferation  via  P2Yi  and  P2Y2  receptors  and 
reduced P2X7 receptor-mediated cell death opposed by a dominant decrease in cell 
numbers as a result of increased P2Xs receptor-mediated differentiation (which is in 
effect antiproliferative).  Thus, increased keratinocyte P2X5 receptor activity may, 
in part, be accountable for epidermal thinning in CVI.
88Introduction
During the later stages of CVI, skin changes including lipodermatosclerosis 
may occur and lead to epidermal breakdown and ulcer formation.  The healing time 
of venous ulcers varies greatly from months to many years and their management 
may  include  district  nursing,  hospital  admission  and  surgery.  Varicose  vein 
stripping  may  be  indicated  in  the  prevention  of ulcer  formation.  Due  to  the 
chronicity of the disease, its management can be expensive.
Several  mechanisms have been proposed to  explain epidermal  loss  during 
ulcer  formation  and  an  inflammatory  process  is  a  common  underlying  factor. 
Purine receptor activity has already been identified in skin epidermis.  The roles of 
P2X5, P2X7, P2Yi  and P2Y2 receptors in different layers in human skin epidermis 
has  been  described  previously190.  P2Yi  and  P2Y2  receptors  are  involved  in 
keratinocyte  proliferation,  while  P2Xs  receptors  are  associated  with  keratinocyte 
differentiation and P2X7 receptors with keratinocyte cell death190,191.  The balance 
between proliferation, differentiation and apoptosis of keratinocytes helps maintain 
an epidermis of constant thickness. Changes in the expression of these P2 receptor 
subtypes could alter this balance and result in either thinning or thickening of the 
epidermis.
Our study was to  examine the expression of P2Xs,  P2X7,  P2Yi  and P2Y2 
receptors in the epidermis of human lower leg skin and the changes seen in patients 
with CVI.  We examined pre-ulcerated CVI  skin in an attempt to  identify purine 
receptors  on  keratinocytes  prior to  their destruction  and  loss.  If a change  in  P2 
receptor expression occurs does it suggest functional changes of the keratinocytes in 
the different layers which might explain the process by which the epidermis is lost 
in CVI.
89Methods
Tissue
Skin samples  in CVI were obtained from patients undergoing stripping of 
their  primary  varicose  veins.  Reflux  had  been  confirmed  by  either  hand  held 
doppler  or venous  duplex  scanning  by  the  vascular team  prior to  surgery.  Skin 
biopsies at sites of CVI were taken from the medial aspect of the mid lower calf at 
the site of either the distal incision for stripping of the LSV or at the site of a stab 
incision for avulsing a prominent varicose vein.  Biopsies were not taken from the 
ankle.  Elliptical  skin  biopsies  were  obtained  from  5  patients  (2  males  and  3 
females)  aged  46  to  69yrs  (mean  =  56.8yrs).  Sites  of  CVI  consisted  of  skin 
pigmentation in 2 patients (CEAP 4a) and lipodermatosclerosis in 3 patients (CEAP 
4b),  based  on  the  Clinical-Etiology-Anatomy-Pathophysiology16  classification. 
There were no co-existing medical conditions in these patients and none took any 
regular medications.  Healthy control  skin was obtained from  5  patients  (3  males 
and  2  females)  aged  56  to  68yrs  (mean  =  64.4yrs),  undergoing  coronary  artery 
bypass  surgery  involving  harvesting  of the  LSV.  Elliptical  skin  samples  were 
excised from an edge of the LSV incision from the medial aspect of the lower calf, 
corresponding  to  the  area  CVI  skin  samples  were  obtained  from.  Control  skin 
showed no  signs  of CVI  and  reflux was  excluded by hand  held  doppler prior to 
surgery.  Patients  in  the  control  group  were  taking  cardiac  medications  for 
ischaemic  heart  disease,  including  P  blockers,  diuretics,  nitrates,  angiotensin 
converting enzyme  inhibitors and  statins.  Diabetic patients and patients with  skin 
conditions (eg psoriasis, patients on steroids) were excluded from the study. Ethics 
approval  was  obtained  by  the  joint  UCL/ULCH  Ethics  Committees  on  Human 
Research and by the Royal Free Hampstead Research Ethics Committee.
Skin  samples  were  collected  in  Hanks  balanced  salt  solution  (HBSS; 
Invitrogen  Ltd.,  Paisley,  UK)  and  then  frozen  in  isopentane  precooled  in  liquid 
nitrogen.  Samples were sectioned at  10pm on a cryostat (Reichert Jung CM 1800),
90collected on gelatine-coated slides and air dried at room temperature.  Slides were 
stored at -20°C.
Immunohistochemistrv
Polyclonal  P2Xs  and  P2X7  receptor  antibodies  (provided  by  Roche  Palo 
Alto,  CA,  USA)  and  polyclonal  anti-P2Yi  and  anti-P2Y2  receptor  antibodies 
(Alomone Laboratories, Jerusalem, Israel) were kept at -20°C.
Sections were fixed for 4 min in 4% formaldehyde in 0.1 M PBS containing 
0.2% picric acid. Sections were washed three times for 5 min each time with PBS. 
Sections were primarily blocked for 60 min in 10% NHS in 0.1 M phosphate buffer, 
containing  0.05%  merthiolate.  Sections  were  then  incubated  overnight  with  the 
primary receptor antibody at concentrations of 1:100 to  1:200 in  10% NHS in PBS 
with 0.05% merthiolate. On the second day, sections were washed for 5  min three 
times in PBS and then stained with the secondary antibody donkey antirabbit Cy3 
(Jackson  ImmunoResearch  Laboratory,  West  Grove,  PA,  USA)  at  1:300  in PBS- 
merthiolate for 60 min.  Sections were washed three times for 5  min before being 
mounted in Citifluor (Citifluor Ltd, London, UK).
Control experiments were performed by separately omitting the primary and 
secondary  antibodies,  and  by  preabsorbing  the  primary  antibody  with  its 
corresponding  peptide.  Preabsorption was  carried  out  by  adding  the  peptide  at  a 
ratio of 1:1  in  10% NHS  in PBS with 0.05% merthiolate,  leaving for  12 hours at 
4°C,  passing  through  a  syringe  filter  (4mm  with  a  0.2pm  PPmembrane)  then 
centrifuged at 13,000rpms for 5 min using only the supernatant.
Semi-quantitative assessment of the changes in immunofluorescent intensity 
were performed by an independent observer, blinded from the patient group from 
which samples were taken
Tissue samples from 10 patients (5 control and 5 varicose) were 
stained for each purinoceptor.
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H&E slides were prepared by fixing in 4% paraformaldehyde in PBS for 10 
min.  Sections  were  then  washed  in  distilled  water  then  stained  for  20  min  in 
Ehrlichs haematoxylin. Following washing in running tap water, slides were dipped 
in acid alcohol and washed again for 15 min. Sections were then stained in eosin for 
5  min,  dipped in tap water, then washed for  1   min in 70% alcohol,  3  min  100% 
alcohol, another 3 min 100% alcohol, dried for 3 min in xylene, and finally another 
5 min in xylene.  Sections were mounted in eukitt.
Photography
Slides  were  photographed  using  a  Zeiss  Axioplan,  high  definition  light 
microscope  (Zeiss,  Oberkochen,  Germany) mounted with  a Leica DC  200  digital 
camera  (Leica,  Heerbrugg,  Switzerland).  Images  were  converted  from  colour  to 
greyscale using Photoshop (Adobe 5.0, San Jose, USA).
Area Measurement
Low  magnification  images  of  H&E  stained  epidermis  were  taken.  Two 
sections  from  different  areas  of each  skin  sample  from  all  five  patients  in  each 
group were studied.  The epidermal area was then calculated using a Scion Image 
programme  and  expressed  as  mean  area  (pm2)  ±  standard  error  (n).  Statistical 
analysis was carried out using an unpaired Student’s Mest, P < 0.05  was taken as 
significant.
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Sections were cut sequentially. Low power magnification of H&E stains of 
skin epidermis are shown (Figures 3.1a, 3.Id, 3.2a, 3.2d, 3.3a, 3.3d, 3.4a and 3.4d), 
with subsequent sections stained with immunofluorescence shown below at greater 
magnification.
Control  skin  stained  for  P2Yi  (Figure  3.1b)  and  P2Y2  receptors  (Figure 
3.2b)  in the basal  layer of the epidermis, with P2Y2 receptors also present in the 
stratum spinosum.  In CVI skin, P2Yi  receptor staining was markedly increased in 
the basal layer and present in the lower layers of the stratum spinosum in four of the 
five patients (Figure 3.1 e), while P2Y2 receptors were markedly increased in both 
stratum  basale  and  spinosum,  and  extended  further  into  the  spinosal  layer  in  all 
patients (Figure 3.2e).
In control skin, P2Xs receptors stained throughout the stratum spinosum, but 
also  in the  basal  and  granulosal  layers  (Figure  3.3b).  In CVI  skin P2X5  receptor 
staining extended further into the stratum granulosum and immunostaining intensity 
was increased in all layers from all patients (Figure 3.3e).
Staining  in  the  control  skin  agreed  with  previous  studies126’191,  confining 
P2X7 receptors to the uppermost layer of dead cells, the stratum comeum (Figure 
3.4b).  This  staining  was  present  in  CVI  skin,  but  was  markedly  reduced  in  all 
patients (Figure 3.4e).
Control experiments were carried out for each P2 receptor antibody used on 
the  subsequent  section  by  preabsorption  of  the  primary  antibody  with  its 
corresponding peptide. For each P2 receptor antibody, preabsorption of the primary 
antibody resulted in no specific immunostaining (Figures 3.1c, 3.If, 3.2c, 3.2f, 3.3c 
and 3.3f); for the P2X7 receptor, some non-specific staining was observed (Figures 
3.4c and 3.4f). Due to the limited sample size, comparisons between CEAP 4a and 
4b samples in the CVI group were not made.
93The  mean epidermal  areas were  calculated  for 2  sections per  skin  sample 
from the control and CVI groups. The mean epidermal areas (pm2) for the control 
skin  and  in  CVI  were  295  ±  6.7  and  275  ±  5.4  respectively  (Figure  3.5).  The 
epidermal  area  in  CVI  skin  was  significantly  (P=0.0313)  reduced  compared  to 
control skin, indicating that the epidermis was thinner.
94Discussion
Previous  research  on  CVI  skin  has  focused  on  changes  occurring  at  the 
dermal capillaries.  These pathophysiological changes occurring in capillaries may 
explain  the  skin  changes  seen  in  clinical  practice.  However  few  studies  have 
focused  on the  epidermis  itself.  White  cell  infiltration236,  fibrin  deposition13  and 
oedema all occur within the dermis  leading to  a reduced delivery of nutrient and 
oxygen237 to the epidermis and an accumulation of waste products from a reduced 
blood  flow  away  from  the  site  affected.  Oxidative  stress  and  white  cell 
extravasation releases inflammatory mediators  , which are thought to damage the 
epidermis239.  It  is  thought  that  ischaemia  followed  by  reperfusion  worsens  the 
process, leading to the chronic inflammatory state. Reperfusion to the tissue causes 
increased leucocyte activation, releasing reactive oxygen metabolites and hydrolytic 
enzymes, exacerbating the ischaemic injury240.  Whilst dermal changes in CVI have 
been previously reported, little work exists to demonstrate the proliferative changes 
the keratinocytes undergo.
P2Y i and P2Y2 receptors are known to mediate keratinocyte proliferation in 
the  human  epidermis  and  our  controls  match  the  findings  of an  earlier  study  of 
human  ‘leg’  skin  although proliferation marker  staining was  not repeated190.  The 
increased  expression of P2Yi  and P2Y2 receptors  on the basal  layer and  stratum 
spinosum  in  CVI  skin  suggests  increased  proliferation.  The  extension  of P2Y2 
receptor  staining  towards  the  stratum  granulosum  suggests  an  increased 
keratinocyte proliferation extending beyond the basal layer deep into the epidermis. 
CK  14  is  a  cytokeratin  found  on  basal  cells  that  is  lost  upon  keratinocyte 
differentiation.  It  is  greatly  increased  in  suprabasal  layers  in venous  eczema and 
lipodermatosclerosis241 suggesting prolonged proliferation of the basal cells. This is 
consistent with our findings of increased P2Yi and P2Y2 receptors in layers beyond 
the  stratum  basale  in  CVI.  Increased  keratinocyte  proliferation  may  act  as  a 
compensatory  mechanism  to  maintain  epidermal  thickness  in  the  presence  of 
increased differentiation, preventing epidermal thinning and ulceration.
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keratinocyte proliferation and inhibit differentiation through activation of the P2Y2 
receptors209.  Antagonists to P2Y2 receptors are therapeutic targets  in keratinocyte 
hyperproliferation states such as psoriasis209. In melanoma, a lack of P2Y2 receptor 
expression  is  seen;  however  increased  telomerase-induced  proliferation  has  been 
identified  which  may  explain  the  aggressive  nature  of the  malignant  lesion242. 
Hyperproliferative keratinocytes, demonstrated by an increase in integrin pi243, at 
the  edge  of  venous  ulcers  is  consistent  with  increased  proliferation.  The 
inflammatory  process  present  in  CVI  may  increase  keratinocyte  proliferation 
through  increased  activity  of  P2Y2  receptors,  accounting  for  their  increased 
expression.
P2Xs  receptors  are  restricted  to  metabolically  active,  differentiating  cell 
layers of the epithelia and are not associated with mitosis and cell death191.  P2Xs 
receptors  have  been  detected  in  spinous  and  granular  layers,  decreasing  in  its 
intensity  towards  the  outermost  layer191.  It weakly  stained the  basal  layer  in the 
oesophagus  and palate.  Greig et al190  showed the presence  of P2Xs  receptors  in 
these  three  layers  in  human  Teg’  skin,  with  early  keratinocyte  differentiation 
occurring  in  the  stratum  spinosum,  and  late  differentiation  occurring  within  the 
upper spinosal and granular layers. These findings match our control P2Xs receptor 
staining. In CVI skin, the intensity of P2Xs receptor staining increased throughout 
all  three  layers  suggesting  an  overall  increase  in  P2Xs  receptor-mediated 
keratinocyte differentiation, which in effect is antiproliferative.  Some cytokeratins 
expressed  on epithelial  cells  are  established markers  of differentiation.  CK  10,  a 
marker of terminal  differentiation,  has been  shown to  increase  in venous  eczema 
and lipodermatosclerosis in suprabasal layers241. This is consistent with our findings 
of increased P2Xs receptor expression representing an increase in differentiation in 
spinosal and granular layers, although staining with differentiation markers was not 
repeated.
P2X7 receptors on macrophages and lymphocytes have cytotoxic functions 
at sites of inflammation244.  P2X7 receptors are also thought to be  involved in the 
release of IL-lp245, mitogenic stimulation of T lymphocytes246, and the cytoplasmic
96communication between macrophages and lymphocytes247. P2X7 receptor levels on 
monocyte-macrophage  lineage  cells  are  increased  in  sarcoidosis,  where  they  are 
associated with cytotoxicity, maturation and IL-lp release248. P2X7receptor staining 
was seen on the outer layer of dead keratinocytes, the stratum comeum, on control 
skin,  as  previously  reported191,  and  represents  keratinocytes  terminally 
differentiating190.  In CVI,  P2X7 receptor staining was markedly reduced to small, 
scattered areas of the stratum comeum. P2X7 receptors are involved in the induction 
of cell  death249,250,  and might be  a compensatory  change,  which prevents  further 
thinning of the epidermis.
Plasma  levels  of endothelial  leukocyte  adhesion  molecule-1,  intercellular 
adhesion molecule-1  (ICAM-1) and vascular cell adhesion molecule-1  are increased
1
in  response  to  venous  hypertension  .  Increased  expression  of  ICAM-1  in  the 
capillaries and infiltration of T-lymphocytes  and macrophages around the  vessels 
are  seen  in  patients  with  lipodermatosclerosis  .  Allopurinol,  a  xanthine  oxide 
inhibitor, is a free radical scavenger. It also suppresses the production of TNF-a and 
downregulates  the  expression  of  ICAM-1  and  P2X7  receptors  on 
monocytes/macrophages252.  ICAM-1  on  macrophages  attaches  to  T  lymphocytes 
allowing antigen presentation and T cell activation. Thus allopurinol may suppress 
T  cell  activation  and  may  suppress  keratinocyte  P2X7  receptor  expression  and 
reduce keratinocyte cell death.  P2X7 receptors on macrophages and lymphocytes 
have  cytotoxic  functions  at  sites  of  inflammation244.  P2X7  receptors  are  also 
thought  to  be  involved  in  the  release  of  IL-lp245,  mitogenic  stimulation  of  T 
lymphocytes246,  and  the  cytoplasmic  communication  between  macrophages  and 
lymphocytes247.  Thus allopurinol may reduce the skin damage during the chronic 
inflammation seen in CVI.  P2X7 receptor levels on monocyte-macrophage lineage 
cells  are  increased  in  sarcoidosis,  where  they  are  associated  with  cytotoxicity, 
maturation and the release of IL-ip248.
Epidermal  mast  cells  are  found  in  chronic  skin  inflammation  with 
hyperproliferative  epidermis  and  in  chronic  ulcers,  where  mast  cell  granules  are 
found  inside  keratinocytes.  The  mast  cell  mediators  histamine  and  heparin,  and 
human mast cell  lysate have an inhibitory effect on keratinocyte proliferation and
97epithelial growth. It could be concluded that mast cells have an inhibitory effect on 
epidermal  growth253.  ATP  induced histamine release  from mast cells  is mediated 
via P2X7 receptors114,254.  Inhibition of keratinocyte growth may be a result of the 
action of ATP on mast cells.  Mast cells may also act directly on keratinocyte P2 
receptors by releasing ATP and affecting keratinocyte growth112.
CVI  is  associated  with  an  increase  in  production  of  TGF-pi  from
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leucocytes  . This stimulates dermal fibroblasts to differentiate and secrete MMP- 
2.  Increased  MMP-2  activity  results  in  degradation  of  epidermal  basement 
membrane  collagen  type  VI  (a  substrate  for  MMP-2)  and  subsequent  loss  of 
epidermal  integrity256.  Enhanced  MMP-2  expression  has  been  localised  to  the 
perivascular  cuff sites,  dermal  fibroblasts,  leucocytes  and  in  basal  layers  of the 
epidermis257. P2X7 receptor activation has been shown to enhance TGF-pl  mRNA 
expression258. As TGF-pi  and mRNA of MMP-2 are increased in CVI, an increase 
in P2X7 receptor staining might therefore be predicted  in the basal  layer in  CVI. 
However our results showed reduced P2X7 receptor staining in the stratum comeum 
with no P2X7 receptor staining in the basal layer in CVI.
Our results show that CVI skin is thinner than controls.  If the thickness of 
skin decreases with CVI then over time this would lead to continuous thinning of 
the  epidermis  until  it  eventually  breaks  down,  ulcerating.  This  would  follow the 
clinical picture.  In our study we have looked at pre-ulcerated states.  Studies have 
shown that impaired epithelialisation of chronic ulcers is not caused by the lack of 
epidermal  stem  cells,  inadequate  proliferation,  differentiation  or  apoptosis  at  the 
edge of wounds243. Failure of wound healing may reflect the distorted organisation 
of  the  wound  bed  caused  by  infection  and  impaired  nutrient  supply,  altering 
keratinocyte migration at the ulcer edge243. Animal work has previously shown that 
activation of adenosine A2 receptors increase the rate of wound healing.  A2A  and 
A2B   receptor  stimulation  contributes  to  enhanced  fibroblast  and  endothelial  cell 
migration259.  Whether  this  is  due  to  increased  secretion  of vascular  endothelial 
growth  factor or to  inhibition  of the  secretion  of cytokines  or  collagenase  is  not 
known. Our work has focused on the P2 receptors in non ulcerated skin, but the role
98of A2  receptors  on  ulcerated  skin  may  help  further  in  our  understanding  of the 
overall function of purines in CVI skin changes.
In  summary,  increased expression of P2Yi,  P2Y2  and P2Xs  receptors  and 
decreased  expression  of P2X7  receptors  has  been  shown  in  CVI.  Whether  the 
thinner  epidermis  in  CVI  might  be  the  resultant  of  increased  keratinocyte 
proliferation via P2Yi  and P2Y2  receptors,  reduced apoptosis  via P2X7 receptors 
and a dominant antiproliferative effect mediated via P2X5 receptors, requires further 
investigation.  Enhanced  keratinocyte  proliferation  through  targeting  P2Yj  and 
P2Y2  receptors may increase  epidermal thickening,  protecting against breakdown 
and ulceration. Antagonising the actions mediated by P2Xs receptors may reduce its 
antiproliferative effects resulting in a thicker epidermis. It is not clear whether these 
changes in purinoceptor expression found in CVI are of compensatory advantage or 
a secondary consequence.
99Figure 3.1: H&E staining and P2Yi receptor immunostaining 
keratinocytes.  H&E  staining  of control  (a)  and  CVI  (d)  skin 
magnification,  immunofluorescence  shows  staining on  stratun 
control  (b),  with  increased  staining  in  basal  and  spinosal  (SS 
Preabsorption  of  P2Yi  receptors  with  its  peptide 
immunofluorescence (c) and (f).
Control  C \
100Figure 3.2: H&E staining and P2Y2 receptor immunostaining of human epidermal 
keratinocytes.  H&E  staining  of control  (a)  and  CVI  (d)  skin  sections.  At  higher 
magnification,  immunofluorescence  staining  of  P2Y2  receptors  is  present  on 
stratum  basale  (SB)  and  lower  stratum  spinosal  (SS)  layers  in  control  skin  (b). 
Immunostaining  extends  deeper  into  the  spinosal  (SS)  layer  and  is  of a  greater 
intensity  in  CVI  (e).  Preabsorption  of  P2Y2  receptors  with  its  peptide  shows 
minimal immunofluorescence (c) and (f).
Control  CVI
25uM
101Figure 3.3: H&E staining and P2X5 receptor immunostaining of human epidermal 
keratinocytes.  H&E  staining  of control  (a)  and  CVI  (d)  skin  sections.  At  higher 
magnification, immunofluorescence staining of P2Xs receptors is present on basale 
(SB), spinosal (SS) and stratum granulosum (SG) layers in control skin (b). Skin in 
CVI shows the same pattern of staining but of increased intensity (e). Preabsorption 
of P2X5 receptors with its peptide shows minimal immunofluorescence (c) and (f). 
Control  CVI
(a)  (d)
mss
102Figure 3.4: H&E staining and P2X7 receptor immunostaining of human epidermal 
keratinocytes.  H&E  staining  of control  (a)  and  CVI  (d)  skin  sections.  At  higher 
magnification,  immunofluorescence  staining  of P2X7  receptors  is  present  on  the 
stratum comeum (SC) in control skin (b), but staining is markedly reduced in CVI
(e).  Preabsorption  of  P2X7  receptors 
immunofluorescence (c) and (f).
Control
25jliM
25|iM
with  its  peptide  shows  reduced 
CVI
(f>
25|iM
103Figure 3.5: Bar chart representing epidermal area in low magnification images of 
control and CVI skin. Mean epidermal area (pm ) ± standard error (n=5) of control 
(black square) and CVI (white square) skin are shown. The mean of the CVI skin is 
significantly thinner than control epidermis (*P=0.0313).
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104Chapter 4
Purinergic Signalling In Penile Erection
105Abstract
ATP and UDP are known to affect vascular tone via cell surface purine receptors, of 
which there are two families: PI and P2. The activation of P2Y6 receptors has been 
previously reported to  cause vascular smooth muscle contraction.  Our hypothesis 
was  ‘The  P2Y6  receptor  plays  a  short  term  role  in  dilatations  underlying  penile 
erection’.  Human  cavemosal  tissue  was  obtained  from  23  patients  undergoing 
gender  reassignment  surgery.  Fluorescent  immunohistochemistry  and  RT-PCR 
were used to determine the presence of P2Y6 receptors in corpus cavemosal tissue. 
The  effects  of  UDP,  a  P2Y6  receptor  agonist  were  assessed  on  precontracted 
cavemosal  strips  using  organ baths  pharmacology.  Immunofluorescence  and  RT- 
PCR  identified  P2Y6  receptors  on  cavemosal  tissue.  UDP  induced  a  significant 
relaxation of precontracted cavemosal strips, which was significantly diminished by 
a P2Y6 antagonist.  We have  identified the presence  of P2Y6 receptors on human 
cavemosal  tissue,  which  when  activated  induces  cavemosal  smooth  muscle  cell 
relaxation. Purinergic modulation of human cavemosal smooth muscle cells via the 
P2Y6 receptor subtype might play a physiological role in penile erection.
106Introduction
Purines are known to mediate effects in smooth muscle and regulate blood 
vessel tone.  In the penis modulation of smooth muscle  function and blood flow 
regulates  tumescence.  Many  studies  have  shown  that  the  main  neurotransmitter 
mediating relaxation of CSM is a non-adrenergic non-cholinergic neurotransmitter. 
Evidence exists to support the role of adenosine in the erectile process by inducing 
relaxant  effects  on  CSM,  increasing  cavemosal  blood  flow  and  inducing 
tumescence196'200.  Studies  have  shown  ATP  inducing  relaxation  in  CSM, 
stimulating the erectile process34,198,200,201.  At low CSM basal tension, ATP causes 
contraction, thus ATP may act via more than one pathway203.  Possibilities include 
adenosine mediated effects following the breakdown of ATP, and direct effects of 
ATP on P2 receptors.
P2Yj  and P2Y2 receptors have been identified on hamster urethral smooth 
muscle and relaxation to ATP is thought to be P2Y i  receptor mediated, leading to 
NO  release  from the  endothelium204,205,207.  P2X receptors  induce contractions  of 
CSM205.  Lee et al demonstrated the presence of P2Xi and P2X2 in rat CSM210.
Malmsjo et al found that stimulation of P2Yi, P2Y2 and P2Y4 receptors led 
to  relaxation  of the  rat  isolated  mesenteric  artery96.  P2Y6  receptor  stimulation 
contracted the tissue. Chapter 2 demonstrates P2Y6 receptor- mediated contraction 
of longitudinal SMC in the LSV.  As CSM is akin to a modified vascular tissue, it is 
possible that the P2Y6 receptor might have a similar bio-profile in the CSM as in the 
mesenteric  artery.  We  have  examined  the  role  of the  P2Y6  receptor  in  CSM,  to 
identify its possible  role  in detumescence.  P2Y6 receptor-mediated properties on 
CSM may identify targets in the treatment of impotence.
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Tissue
Human cavemosal tissues were obtained (following ethical approval) from 
patients  undergoing  gender  reassignment  surgery  at  Charing  Cross  Hospital, 
London, UK.
Immunohistochemistrv
Tissue was collected in Hanks balanced salt solution (HBSS  from Gibco). 
Following  dissection,  cavemosal  muscle  was  frozen  in  isopentane,  precooled  in 
liquid nitrogen.  10pm  sections were  cut on  a cryostat (Reichert Jung  CM 1800), 
collected on gelatine-coated slides and air dried at room temperature.  Slides were 
stored at -20°C.  Sections were fixed for 4 min in 4% formaldehyde in 0.1 M PBS 
containing 0.2% picric acid.  Sections were washed three times for 5 min each time 
with  PBS.  Sections  were  primarily  blocked  for  60  min  in  10%  NHS  in  0.1M 
phosphate  buffer,  containing  0.05%  merthiolate.  Sections  were  then  incubated 
overnight with the primary polyclonal anti-P2Y6 antibody (obtained from Alomone 
Laboratories,  Jerusalem,  Israel)  at concentration  1:200  in  10% NHS  in PBS  with
0.05% merthiolate.  On the second day, sections were washed for 5 min three times 
in  PBS  and  then  stained  with  donkey  anti-rabbit  Cy3  (Jackson  Immunoresearch 
Laboratories,  USA),  the  secondary  antibody,  at  1:300  in  PBS-merthiolate  for  60 
min.  Sections were washed three times for 5 min before being mounted in Citifluor 
(Citifluor Ltd,  London,  UK).  Control  experiments were performed by separately 
omitting  the  primary  and  secondary  antibodies,  and  by preabsorbing  the  primary 
antibody with its peptide.  Preabsorption was carried out by adding the peptide at a 
ratio of 1:1  in  10% NHS  in PBS with 0.05% merthiolate,  leaving for  12 hours at 
4°C,  passing  through  a  syringe  filter  (4mm  with  a  0.2pm  PPmembrane)  then 
centrifuged at 13,000rpms for 5 min using only the supernatant.
108Haematoxvlin and Eosin staining
H&E slides were prepared by fixing in 4% paraformaldehyde in PBS for 10 
min.  Sections were washed in distilled water and stained for 20 min in Ehrlichs 
Haematoxylin.  Following washing in running tap water, slides were dipped in acid 
alcohol and washed again for  15  min.  Sections were then stained in Eosin for 5 
min,  dipped  in  tap  water,  then  washed  for  1   min  in  70%  alcohol,  3  min  100% 
alcohol,  another  3  min  100%  alcohol,  cleaned  for  3  min  in  xylene,  and  finally 
another 5 min in xylene.  Sections were mounted in eukitt.
Photography
Slides  were  photographed  using  a  Zeiss  Axioplan,  high  definition  light 
microscope  (Zeiss,  Oberkochen,  Germany) mounted with a Leica DC  200  digital 
camera (Leica, Heerbrugg, Switzerland).
Reverse Transcription-Poivmerase Chain Reaction (RT-PCR)
RNA  extraction:  Equipment  was  decontaminated  using  an  autoclave.
Where  this  was  not  possible,  equipment  was  decontaminated  with  RNaseZap 
(Ambion) following the suppliers instructions and placed in a laminar flow cabinet. 
Powder  free  gloves  were  worn  throughout.  Tissue  was  collected  in  RNAlater 
(Ambion)  and transported to  the  laboratory.  Unused tissue  was  frozen  in  liquid 
nitrogen and kept at -80°C.  In an air extraction cupboard, tissue was chopped with 
scissors into small pieces in a glass beaker containing TRIzol Reagent (GibcoBRL), 
(lml per 50mg tissue).  Tissue was then homogenized at high speed for 30secs, left 
covered  for  lOmin  and  homogenized  again  for  30secs.  Separated  out  into  small 
tubes, the solution was centrifuged at 12,000g for lOmin at 4-8°C.  The supernatant 
was pipetted out into clean tubes, chloroform added (0.2 ml /ml TRIzol) and shaken
109well.  Following  centifugation,  as  before,  the  supernatant  was  pipetted  out  into 
clean tubes and isopropyl alcohol added (0.5ml/ ml Trizol).  Solutions were left for 
lOmin and centrifuged once more.  The  supernatant was discarded and the RNA 
pellet-like gel at the bottom was washed with 75% ethanol (1 ml/ml TRIzol).  The 
solution  was  centrifuged  at  7,500g  for  5min  at  2-8°C.  The  supernatant  was 
discarded, the RNA redissolved in lOOpl distilled water and incubated for lOmin at 
55-60°C.  Optical densitometry was used to calculate the volume of RNA present.
RNA amplification:  To an RT-PCR bead (Amersham pharmacia biotech), 
first-strand primer, DEPC water and RNA were added totalling 49pl, following the 
manufacturer’s  instructions.  Placed  in  an  incubator,  the  sample  was  exposed  to 
42°C for 30mins followed by 95°C for 5min.  After adding lpl of the P2Y6-specific 
primer, the tube was exposed to 40 cycles of 95°C for 30secs, 62°C for  1   min and 
72°C for lmin.  lOpl of loading buffer was added to the final solution.
Ethium bromide agarose gel was prepared by adding 4g of 2% agarose in 
200mls  of  TAE  Buffer,  warming  until  dissolved,  then  adding  lOpl  of  ethium 
bromide.  When  the  gel  was  set,  lOpl  of RNA  solution  was  placed  in  a  well, 
alongside a DirectLoad wide-range DNA marker (Sigma), and 100V of 320mA was 
passed through for 1  hour.  Ultraviolet images of the gel were taken using a multi­
function camera (BIO-RAD Fluor-S™ Multiimager).
Pharmacology
Isolated human cavemosal tissues were cut into strips of approximately 2 x 
5 mm length. The strips were mounted vertically in  10 ml organ baths containing 
Krebs solution. The Krebs solution (pH 7.2) had the following composition (mM): 
NaCl  133, KC1  4.7,NaH2P04  1.35,NaHC03  16.3,MgS04  0.61,CaCl2  2.52 and 
glucose  7.8.  The  tissue  strips  were  maintained  at  37±1  °C  and  bubbled  with  a 
mixture of 95% 0 2 and 5% C02. An initial tension of 2 g was applied and the strips 
were allowed to equilibrate for  1   h before being challenged with KC1  (124 mM),
110which was repeated at the end of the experiment. Results were only accepted if both 
KC1 responses varied in magnitude by less than 10%.
Initial  experiments  showed  that  UDP  (a  P2Y6  receptor  agonist)  caused 
cavemosal  relaxations.  Subsequently,  all  tissues  were  precontracted  with 
phenylephrine  (PE)  lO^M to quantify UDP-induced relaxations (10'3M  or  lO^M, 
n=9  for  each  concentration).  In  some  experiments,  cibacron  blue  3GA  (a  P2 
receptor antagonist; lO^M, n=9) or L-NAME (a NO synthase inhibitor; lO^M, n=9) 
was  added to  the  strips  and  left  for 20  min prior to  re-exposure to  UDP  10'3M. 
Control experiments were also performed examining the effect of distilled water on 
the UDP-induced relaxation using PE-precontracted strips.
PE, UDP, cibacron blue 3GA and KC1 were supplied by Sigma Chemical 
Co. (Poole, UK).
Statistical Analysis:
Comparisons were made between UDP alone and following exposure to 
cibacron  blue  3GA,  L-NAME  or distilled  water  using  a  one-way  analysis  of 
variance (ANOVA) followed by a post hoc test (Bonferroni’s). A probability of 
P<0.05  was  taken  as  significant.  Results  are  presented  as  mean  values  +/- 
standard error of mean (SEM).
RT-PCR (controls!
Omitting the initial RNA during amplification acted as a control, with no 
band appearing on the gel (result not shown).  Further control experiments that 
could  have  been  performed  include  omitting  the  P2Y6-specific  primer  during 
RNA amplification and repeating the experiment with a tissue known to contain 
the  P2Y6  receptor  (positive  control).  RT-PCR  was  performed  on  CSM  tissue 
from 4 patients (n=4).
IllResults
Immunohistochemistrv
Subsequent tissue sections underwent one of three staining techniques: H&E 
staining  identified  the  presence  of  muscle  cells  (Figure  4.1a), 
immunohistochemistry of the P2Y6 receptor antibody showed positive staining on 
the muscle cells (Figure 4.1b), and immunohistochemistry following preabsorption 
with  the  P2Y6  receptor  antibody  peptide  showed  reduced  staining,  the  control 
(Figure 4.1c).  This demonstrates the presence of P2Y6 receptors on CSM
P2Y6 receptor staining was seen on all 7 patients immunostained.
RT-PCR
RT-PCR  demonstrated  the  presence  of a  band  at  364  base  pairs,  which 
corresponds to the P2Y6 receptor mRNA in cavemosal tissue (Figure 4.2).  No other 
bands were seen during this preparation.  The wide range DNA ladder is seen on the 
left side.
Pharmacology
UDP  caused  a  significant  and  sustained  relaxation  of  PE-precontracted
tissue at both concentrations used (lO^M, 4.9 +/- 0.8;  10'3M,  15.7 +/- 2.8, both
p < 0 .01)  when  compared  with  controls  (distilled  water).  The  UDP-mediated
relaxation (10*3M) was significantly reduced by cibacron blue 3GA  lO^M (8.2 +/-
1.5,  p<0.05).  Whilst in contrast,  L-NAME  lO^M had no  significant  effect  on
UDP-mediated relaxations (10'3M, 17.1 +/- 4.4) (Figure 4.3).
Ecto-enzymes (surface enzymes) may convert UDP to UTP (requiring
the  uptake  of ATP),  producing  agonist  actions  of UTP  on  P2Y2  and  P2Y4
receptors. Relaxations recorded may be a combination of UTP and UDP actions.
112Discussion
Male erectile dysfunction affects 5% of men in their 40’s, and increases in
incidence  with  age.  Causes  include  psychogenic,  vasculogenic,  neurological,
endocrine  (diabetes),  traumatic  and  drug  related.  Strong  evidence  exists  linking
LUTS and ED44.  P2Xi receptor mediated detrusor muscle contraction is enhanced
in LUTS  in rabbits260.  Purinergic signalling alterations affecting LUTS  may also
have effects on ED.  Adenosine and ATP induce relaxation in CSM.  Sensitivity is
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enhanced with  diabetes  and with  increasing  age  *   .  This  purinergic  alteration 
could be  a result of new nerve proliferation that release purines,  upregulation of 
current purinergic receptors or enhanced purine receptor sensitivity that may occur 
during the  diabetic  and  ageing  changes  of the  CSM.  Diabetes  is  also  known to 
impair NO  mediated  CSM  relaxation,  leading to  ED262.  Purinergic  signalling  is 
known  to  be  contributory  in  the  proliferation  of  vascular  smooth  muscle  and
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endothelial cells as well as cell death  . It is possible that the enhanced purinergic 
bioactivity  in  diabetes  and  ageing  would  lead  to  development  or  worsening  of 
penile  atherosclerosis  in  the  long  term.  Therefore,  although  the  purinergic 
enhancement  might  be  compensatory  initially,  it  could  be  detrimental  to  erectile 
function as time progresses in ageing and diabetic patients.
Using  immunohistochemistry  and  RT-PCR  techniques,  the  presence  of 
mRNA for the P2Y6 receptor and the receptor itself have been detected on CSM for 
the  first time.  Organ bath  studies  revealed  that  P2Y6  receptor  activation  causes 
sustained relaxation of the CSM.  Greater relaxation of the CSM was recorded with 
a more concentrated UDP solution.  The significant reduction in relaxation in the 
presence of cibacron blue 3GA confirms a P2Y6 receptor-mediated relaxation.  This 
finding  is  in  marked  contrast  to  earlier  studies  on  endothelium  denuded  rat 
mesenteric  artery  and  human  cerebral  artery  where  vasoconstriction  was 
reported96,263.  This discrepancy implies that activation of the P2Y6 receptor has a 
range of physiological functions with species and tissue variation.
113P2Y receptor activation has been reported to induce endothelium-dependent 
relaxation of human  CSM  via NO production205.  However  we  did  not record  a 
significant reduction in relaxation in the presence of the NO synthase inhibitor L- 
NAME.  It is possible that there are two independent pathways involved in CSM 
relaxation: a P2Y6 receptor-mediated pathway and a NO-mediated pathway.  CSM 
stretching  during tumescence  may  stimulate the  release  of ATP  from  endothelial 
cells which may lead to relaxation, as is seen in the bladder264.  Studies showed that 
NO  and  ATP-sensitive  potassium  channels  play  a  significant  role  in  modulating 
human  CSM relaxation,  and therefore,  erectile  capacity265,266.  Adenosine  relaxes 
CSM via activation of the potassium ATP channels  .  Both ATP and adenosine 
may  therefore  mediate  relaxation  either  by NO  production  or  via  ATP-sensitive 
potassium  channels.  It  must  be  remembered  that  ATP  is  hydrolysed  by 
ectonucleotidases  to  adenosine.  Both  A2A  and  A2B   have  been  demonstrated  on 
CSM.
VIP is thought to play a role in the erectile process267.  Chiang PH et al196 
demonstrated that the combination of adenosine and prostaglandin (PGEi) is more 
effective  than  PGEi  alone  in  promoting  tumescence  in  man.  This  suggests  that 
targeting purinergic  pathway,  possibly mediating the  P2Y6 receptor,  may  form  a 
novel  therapeutic  option  in the treatment  of erectile  dysfunction,  in  combination 
with other erectogens such as PDE5 inhibitors and PGEi.  Modem drugs designed to 
increase  arterial  blood  flow  into  the  penis  to  promote  tumescence  may  fail  in 
practice.  Reduced venous outflow is vital to the process.  PGEi is able to induce a 
valid  erection,  but adenosine  alone  is  unable to  do  so.  Studies  into this  showed 
increasing  concentrations  of  PGEi  increased  dorsal  penile  vein  tone  (reducing 
venous  outflow)  whilst  adenosine  showed  no  venous  effect.  However  in  NA 
precontracted  venous  strips,  adenosine  induced  an  almost  complete  relaxation 
(increasing  venous  outflow)199.  Adenosine  is  thought  to  relax  both  arterial  and 
venous vessels explaining why adenosine alone can not produce an erection.
Our  findings  reinforce  the  evidence  that  suggests  involvement  of  the 
purinergic signalling system in the erectile process through the P2Y6 receptor.
114Figure 4.1: Immunohistochemisty of cavemosal smooth muscle. Three consecutive 
sections are shown; stained with H&E (a), immunofluorescent staining with a P2Y6 
receptor  antibody  (b)  and  immunofluorescent  staining  with  a  P2Y6  receptor 
antibody following preabsorption with its peptide (control) (c).
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IFigure 4.2: RT-PCR gel electrophoresis showing a DNA ladder (left side) and the 
presence of the 364 base pair mRNA of the P2Y6 receptor in cavemosal muscle 
(right).
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117Figure 4.3:  Bar chart representing  organ bath  pharmacology results.  Cavemosal 
muscle relaxation is expressed as a percentage of the overall contraction induced by 
10'4M  phenylephrine.  Relaxations  were  measured  to  the  following  agents  with 
standard  error  of  the  mean  shown:  DH2O   (distilled  water),  UDP  (uridine 
5’diphosphate) at  10‘4 and  10'3 M concentrations, UDP  10'3M and L-NAME  10'4M 
(a  nitric  oxide  synthase  inhibitor),  and  UDP  10'3M  and  Cib  blue  3GA  10'4M 
(Cibacron blue 3GA is a P2Y6 antagonist).
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118Chapter 5
General DiscussionThe role of purines  in CVI has been explored in chapters 2  and 3  of this 
thesis.  Purine receptor related changes have been identified between control  and 
CVI tissues suggesting that purine-mediated actions are affected during CVI.  This 
is the first time an association between purines and CVI has been demonstrated and 
opens  up  potential  therapeutic  pathways.  Chapter  4  has  identified  relaxant 
properties of the P2Y6 receptor on CSM.  This is a new discovery and may help in 
our understanding of tumescence and subsequent clinical management of ED.
Purine receptors on varicose veins
Many studies exist on circular smooth muscle contraction of the LSV.  This 
is the first study to contract longitudinal strips of LSV.  Longitudinal fibres exist in 
both the  intima and the adventitia of the LSV and I have aimed to  contract these 
using the longitudinal axis of the vein, though it is impossible to separate them from 
the circular fibres.  Circular muscle fibres that spiral along the long axis of the vein 
may account for contractions along the long axis.  Both circular and longitudinal 
muscle contracted to NA and a P2Xi  receptor agonist, with reduced  contractions 
seen in the varicose vein.  Stimulation of P2Yi, P2Y2 and P2Y6 receptors contracted 
longitudinal  fibres  only,  with  reduced  contractions  seen  in  varicose  veins. 
Immunostaining  of  PXj  receptor  decreased  and  of  P2Yi  and  P2Y2  receptors 
increased in varicose veins, whilst that of P2Y4 and P2Y6 receptors remained the 
same.  This  summary  of findings  addresses  the  first  part  of the  first  hypothesis 
(purinoceptor  changes  occur  between  control  and  varicose  LSV);  in  that 
purinoceptor variation does occur between the two tissues.  The second part of the 
hypothesis (these changes are related to functional properties of the smooth muscle, 
either causal or consequential to varicose veins) refers to the EM findings.  Here 
structural differences were identified along with synthetic phenotyped SMC in the 
varicose  vein.  The  immunohistochemical  findings  of reduced  P2Xj,  increased 
P2Yi  and  P2Y2  receptors  in  varicose  tissue  supports  a  purine  receptor-mediated
120phenotype change of the SMC and thus altered function.  The first hypothesis has 
therefore been answered and the findings can be summarized in Fig 5.1
Whilst the findings describe a phenotype change in the varicose tissue, it is 
unclear whether this causes the varicose changes to occur, or whether this is a result 
of the varicose change and is a compensatory effect.  It is still uncertain whether the 
aetiology of varicose veins  is a defect within the muscle wall,  such as an altered 
SMC  phenotype,  or  due  to  refluxing  valves.  A  refluxing  valve  would  increase 
venous pressure and may stimulate structural changes.
121Fig  5.1  Diagram  representing  the  role  of  purinoceptors  in  the  LSV  based  on 
findings in this research.  ATP is released at the neuroeffector junction and acts on 
P2Xi,  P2Yi,  P2Y2  and  P2Y6  receptors  mediating  vasoconstriction.  In  varicose 
veins, P2Yi and P2Y2 receptor mediated actions include an increase in collagen and 
elastin deposition in the media.  Shear stress stimulates ATP and UTP release from 
the  endothelial  cells  which promotes  vasodilatation via P2Yi  and  P2Y2  receptors 
respectively.
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122Targeting  purine  receptors  on  the  LSV  may  have  a  role  in  preventing 
varicose changes occurring.  Competitive antagonists to P2Yi  and P2 Y2 receptors 
may  inhibit  synthetically  phenotyped  SMC,  reducing  collagen  deposition  and 
inhibiting structural varicose changes occurring.  As varicose changes occur over 
time,  antagonistic  action  would  need  to  either  be  long  lasting  or  regularly 
administered.  However  P2Yi  and  P2Y2  receptor  antagonists  would  also  reduce 
their  contractile  actions,  as  noted  in  the  varicose  tissue.  The  P2Xi  receptor 
mediated the greatest constriction out of the purinoceptors studied.  Similar findings 
are seen on other tissues where the P2Xj receptor mediates the greatest constriction. 
P2Xj  receptor  agonists  may  increase  LSV  constriction  and  strengthen the  vessel 
wall in varicose veins.  Increased vein wall tone may prevent separation of the valve 
cusps  and  subsequent reflux,  a  factor that  leads  to  CVI.  This  might reduce  the 
progression  of varicose  veins,  with  long  term  agonist  action  likely  to  be  more 
beneficial.  Targeting LSV P2Xi receptor would prove challenging.  A systemically 
acting agonist would act on P2Xj  receptors on  smooth muscle in numerous  sites 
causing  vasoconstriction,  eg  coronary  and cerebral  arteries,  with potentially  fatal 
outcomes268,269.  P2Yi  and  P2Y2  antagonists  would  have  systemic  actions  on
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platelets,  immune cells  and blood vessel  EC  ’  ’  .  A technique to reduce the 
systemic toxicity might involve  isolation of the LSV  from the femoral  vein with 
direct pressure over the saphenofemoral junction, and intravenous injection of the 
drug into the LSV itself.  The drug would need to act quickly and have a short half 
life  (approximately  3  seconds)  in the  blood  stream to  prevent  systemic  damage 
when the pressure over the saphenofemoral junction is released.  The drug would 
ideally  be  long  acting  when  inside  the  vein  wall  media  and  out  of the  lumen. 
Whether a drug is able to work in this manner remains to be seen.  An alternative 
would  be  to  apply topical  drugs  over prominent  superficial  varicose  veins.  The 
drug would need to diffuse through the skin, subcutaneous fat and into the vein in 
order to be effective.  However if the drug diffused into the lumen, then systemic 
effects could occur.
123The  LSV has  important uses  in bypass  surgery.  Vein grafts have limited 
lifespans  and  their  architecture  changes  when  sited  within  the  higher  pressured 
arterial  system.  Intimal  hyperplasia has been reported  along with migration and 
proliferation of de-differentiated SMC185.  ATP is released in large amounts from 
injured cells103.  Atherosclerosis develops following EC injury; hence it is thought 
that ATP is released during the initial stages of atherosclerosis.  ATP and adenosine 
have potent actions in SMC and EC growth, migration, proliferation and death103. 
Vascular EC are exposed to blood flow variation which plays a major role in the 
development  of atherosclerosis.  The  shear  stress  that  occurs  during  blood  flow
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changes leads to ATP and UTP release from EC  .  These purines may mediate the 
balance  between  proliferation  and  apoptosis  during  the  development  of 
atherosclerosis.  P2X4  and  P2Y2  receptors  on  EC  are  thought  to  mediate 
proliferation during atherosclerosis of the LSV when used as an arterial graft  .  If 
P2Yj  and P2 Y2 receptors are upregulated and P2Xi  receptor downregulated in the 
elevated  pressure  system  seen  in varicose  veins  and  CVI,  as  our results  suggest, 
then similar receptor upregulation may explain SMC proliferation seen in the higher 
pressure system during atherosclerosis.  Taking our findings further, P2Yj and P2Y2 
antagonists may reduce the development of atherosclerosis.  This would have huge 
clinical  implications,  as  atherosclerosis  is  an underlying  factor in many  common 
conditions  including  myocardial  infarctions,  angina,  cerebrovascular  events  and 
peripheral  vascular disease.  However it  should be noted that no  functioning EC 
where detected on the  LSV tissue  samples used in chapter 2  and hence were not 
studied.  EC function is essential to atherosclerosis, where damage to their integrity 
initiates pathways leading to atherosclerosis.
Our findings excluded purine-mediated actions in EC, however interaction 
between  EC  and  SMC  does  exist.  In  the  saphenous  vein,  proven  endothelium- 
mediated vasodilators include  5HT, ACh,  Substance P,  VIP  and bradykinin272* 274. 
ATP is thought to mediate vasodilatation via EC production of NO, endothelium- 
derived hyperpolarizing factor and prostanoids, via P2Yj, P2Y2 and P2Y4 receptors, 
but  this  has  not  been  demonstrated  on  the  saphenous  vein  endothelium  to 
date61,61,89,89,275,276.  Purine  mediated  actions  on  saphenous  vein  EC  are  likely  to
124result in vasodilatation.  Reducing vasodilatation increases vein wall tone and may 
prevent  varicose  changes  occurring.  Conversely  a reduced  vasodilatation would 
reduce the blood flow out of the leg possibly leading to a greater venous pressure 
and thus promoting CVI  and varicose vein development.  Whether EC  function is 
affected in varicose veins is unknown.  This is an area that has not been investigated 
in this study.  Obtaining healthy intact endothelial cells has proved difficult.  The 
vein  is  handled  during  its  surgical  preparation  and  this  is  likely  to  damage  the 
delicate  EC.  Greater  exposure  of the  vein,  with  a  larger  incision,  to  reduce  its 
handling during surgery may be challenged by an ethical committee.  Other sources 
of LSV  could  be  from  patients  undergoing  amputation  for trauma  or  ischaemia, 
however proximal LSV would not be obtained.  In these scenarios handling of the 
vein could be avoided during the amputation surgery.  The LSV in an ischaemic leg 
would not be an ideal  control  as the venous blood would contain  lactic acid and 
other potentially harmful chemicals that may directly damage the EC.  Using animal 
(eg rat)  LSV may be an alternative model.  Creating a CVI  environment may be 
obtained  by  narrowing  the  diameter  of the  proximal  LSV  with  a  ligature  thus 
reducing  blood  flow  through  its  lumen,  elevating  the  pressure  proximal  to  the 
ligature, and possibly resulting in valve reflux.  However a CVI animal model may 
compensate the greater pressure in the LSV by shunting more blood into the deep 
veins.  This model works on the theory that varicose veins develop from refluxing 
valves  leading  to  elevated  pressure  and  vein  dilatation.  If the  main  cause  of 
varicose veins is with the SMC function, then this model will be ineffective.
Whilst varicose veins  are  common, their severity varies  greatly.  In  some 
patients, varicose veins continue to develop and progress, leading to skin changes of 
CVI,  whilst  in  others,  varicose  changes  occur  and  remain  stable  with  no 
deterioration.  Whether its severity is due to the degree of elevated venous pressure, 
the function of the valves or due to changes occurring within the muscle wall itself 
is unclear.  A combination of these factors may control the extent of the varicose 
changes.
125Purine receptors on CVI epidermis
Many of the earlier studies of purines focused on their short term effects that 
occur in neurotransmission and secretion.  Purine mediated trophic functions in the 
epidermis  are  a  recent  discovery277.  This  is  the  first  study  to  date  where 
immunostaining has demonstrated purine receptors in CVI epidermis and compared 
the findings to control epidermis.  Chapter 3’s findings of increased P2Yi, P2Y2 and 
P2X5  receptor  staining  and  reduced  P2X7  receptor  staining  in  the  CVI  skin 
represents  altered  expression  of these  purine  receptors.  An  alteration  of their 
expression is likely to reflect changes  in receptor activity and therefore receptor- 
mediated effects.  To an extent the second hypothesis (purine-mediated effects on 
keratinocytes change in CVI skin) has been addressed, although the precise effect 
has not been demonstrated.
126Fig 5.2 Diagram representing purine receptor changes occurring in CVI epidermis 
based on findings in this research.  Receptor staining on control is shown in black. 
Increased  intensity of receptor staining in CVI  shown in red.  Corneal staining of 
P2X7 (blue) stains positive in control, but weakly stains in CVI skin.
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127The management of varicose veins aims to prevent the development of CVI. 
In the presence of venous ulcers, varicose vein surgery still has a role,  alongside 
compression  bandaging,  skin  grafts  and  numerous  dressings  including  vacuum 
pump therapy278.  Alteration of the purine mediated trophic effects in keratinocyte 
proliferation,  differentiation  and  death  may  inhibit  the  development  of  CVI 
epidermal changes and promote venous ulcer healing.  Potential advances in both 
ulcer prevention and ulcer healing may be  obtained.  CVI  progresses  over many 
years,  hence  targeting  purine  receptors  in  the  epidermis  would  be  a  long  term 
therapy.  Application of purine agonists / antagonists may exist as  a long  lasting 
topical cream wiped over the leg skin, or possibly an implant that could be inserted 
under the skin that slowly releases the agonist / antagonist.  Incorporating a 24hr 
lasting  agonist /  antagonist  into  a moisturiser that  is  daily  applied  to  the  legs  is 
likely to be most successful.
P2X5  antagonists  would  inhibit  keratinocyte  differentiation.  This  would 
have  an  anti-proliferative  effect,  maintaining  a  thicker  stratum  spinosum  and 
granulosum  by  preventing  keratinocyte  differentiation.  As  a  keratinocyte 
differentiates,  it  advances  outwards  towards  the  comeum,  losing  its  proliferative 
role within the epidermis.  However systemic absorption of P2Xs antagonists may 
target other organs including the oesophagus, bladder, kidney and spinal cord279'282. 
Antagonists to P2X7 may reduce apoptosis in the outer epidermal layer.  This may 
result in a thicker stratum granulosum and reduce the loss of keratinocytes from the 
comuem.  Systemic absorption of a P2X7 antagonist may have unwanted effects on 
the pancreas,  lung  and  immune  system116,117,283.  P2Yj  and  P2Y2  agonists  would 
promote keratinocyte proliferation.  In chapter 3 immunostaining of both receptors 
was increased suggesting that proliferation was already increased in CVI.  Further 
agonist  action  on  these  receptors  would  promote  epidermal  thickening.  The 
increased  activity  of both  receptors  in  CVI  is  proposed  to  be  a  compensatory 
mechanism  preventing  epidermal  loss.  It  should  be  noted  that  increased 
keratinocyte proliferation increases the risk of DNA mutations and has neoplastic 
potential.  A side effect of P2Yi  and P2Y2 receptor agonists may be an increased 
risk of squamous and basal cell carcinomas.
128Chapter  3  demonstrates  the  variation  of immunostaining  different  purine 
receptors between control  and CVI  skin.  Simultaneous staining of these  sections 
with trophic  markers,  as  described by Greig et al190,  would  confirm the trophic 
roles of these receptors, rather than assuming they have identical functions seen in 
previous studies.  Double labeling of P2Yi receptors with Ki-67 and P2Y2 receptors 
with proliferating cell nuclear antigen (PCNA) would demonstrate that the increase 
in staining of these  receptors on their respective epidermal  layers  coincided with 
increased cellular proliferation.  Double staining of P2Xs receptors with cytokeratin 
K10 or involucrin would strengthen our theory that the increase in its staining in 
CVI  reflects  increased  early  and  late  keratinocyte  differentiation.  In  the  same 
manner,  a  reduced  P2X7  receptor  staining  along  with  colocalised  staining  with 
caspase-3  or  TdT-mediated  dUTP  nick  end  labeling  strengthens  the  case  for 
reduced apoptosis in the  stratum comeum in CVI.  A mismatch between receptor 
staining  and  trophic  marker  would  suggest  that  variations  in  the  purine  staining 
intensity are due to new unidentified functions of the receptors.
Skin  sections  from  classes  CEAP  4a  and  4b  were  used  in  the  study. 
Comparing two different CEAP classes along with a control might reveal a trend in 
the  keratinocyte  function  as  the  skin  deteriorates  with  progression  of  CVI. 
Comparing classes 4a with 4b would be an appropriate comparison, as skin changes 
would  be  present  and  the  epidermis  would  still  be  intact  (no  active  ulceration 
present).  However due to the limited sample size, comparisons between the CEAP 
classes were not made.
The  findings  in  chapter  2  suggest  an  association  between  LSV  SMC 
phenotype,  purinoceptor  expression  and  changes  occurring  in  varicose  veins. 
Chapter  3  describes  an  association  between  skin  keratinocyte  function, 
purinoceptor expression and changes occurring with  CVI.  These associations 
are observational  only and are not definitive proof.  Patient group differences 
and  experimental  limitations  both  weaken  the  strength  of these  associations. 
Further work is needed to fully validate these purinoceptor hypotheses.
129Purine receptors on cavernosa! smooth muscle
Immunohistochemistry and PT-PCR have demonstrated the presence of the 
P2Y6  receptor  in  penile  CSM,  and  organ  pharmacology  has  shown  its  relaxant 
properties are NO independent.  The hypothesis  ‘The P2Y6 receptor plays a short 
term role in dilatations underlying penile erection’ has been addressed as P2Y6 has 
been shown to relax CSM and this is thought to induce tumescence.
The tumescence process may occur due to a positive feedback mechanism 
until a limiting factor is reached.  Nerve stimulation may initiate the process with 
the release of ATP from sympathetic nerves and subsequent adenosine production, 
or with ACh, released from the parasympathetic nerves.  However an increase in 
blood pressure or pulse rate may increase penile blood flow resulting in endothelial 
cell production of ATP, UTP and NO.  NO production leads to relaxation.  ATP and 
its  breakdown  products  stimulate  A2A   and  A213  receptors  resulting  in  relaxation. 
Relaxation and a subsequent increase in arterial blood flow may promote further EC 
production of NO, ATP and UTP producing a positive feedback mechanism.  The 
limiting  factor  in  this  process  is  unknown.  An  elevated  arterial  flow  will 
compromise  the  venous  outflow  and  eventually  the  penile  pressure  will  prevent 
further arterial inflow.  How the process is reversed in unknown.  A drop in blood 
pressure  may  be  the  initiating  factor,  reducing  EC  production  of NO  and  ATP. 
Increased  NA  production  from  sympathetic  nerves  or  increased  P2Xi  and  P2X2 
CSM  receptor  activity  is  another  possible  mechanism  as  both  lead  to  muscle 
contraction reducing arterial  blood flow.  P2 Y6 receptors  in the media have been 
shown to mediate relaxation; however the source of its agonist is unknown.
130Fig 5.3 Diagram representing purine receptor activity on cavemosal smooth muscle. 
Perivascular nerves  in the  adventitia release  ATP  and NA  as  cotransmitters  from 
sympathetic nerves which result  in  CSM contraction mediated by P2Xj  and  P2X2 
purinoceptors  and  ai  receptors  respectively.  ATP  is  broken  down  to  adenosine 
which  stimulates A2A  receptors  in the  media resulting  in muscle  relaxation.  ACh 
released  from  parasympathetic  nerves  stimulates  Ml  receptors  resulting  in 
relaxation.  P2Y6 receptor stimulation leads to relaxation.  In EC, stress and stretch 
releases  UTP  and  ATP  which  stimulate  P2Y2  receptors  leading  to  NO  mediated 
relaxation.  In the lumen, ATP is broken down to ADP and adenosine which act on 
P2Y1  and A2B  receptors respectively resulting in relaxation.
Sympathetic Nerves  Parasympathetic Nerves
ADP  \  
Adenosine
ai
relaxation contraction relaxation
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Stretch
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Stretch
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131P2Y6 agonists should mediate CSM relaxation and encourage tumescence. 
Excessive  relaxation  would  be  painful,  impair  venous  outflow  in  the  penis  and 
result in structural damage, possibly preventing future erections.  Impaired venous 
outflow  may  result  in  ischaemia  and  its  consequences.  Agonist  effects  would 
ideally last for approximately 30 mins, allowing time for intercourse and reducing 
the  discomfort  of  prolonged  tumescence.  Agonists  applied  locally  eg
intracavemosal  injections,  may  treat  erectile  dysfunction  whether  the  cause  is 
traumatic, diabetes, psychological or neurological.  The benefit of a reduced venous 
outflow means there will be less release of the agonist into the systemic circulation 
and thus fewer complications.  Systemic complications may include excess human 
nucleotide  peptide  induced  IL-8  release  and  a  subsequent  overactive  immune 
system, and an increased risk of inflammatory bowel disease284,285.
UTP is known to be released from EC due to shear stress and stretch.  EC’s 
are a source of UTP, which we speculate breaks-down to UDP and stimulates the 
P2Y6 receptor on smooth muscle to elicit vasodilatation.  To clarify this source an 
EC  toxin  would  be  necessary  to  prevent  UTP  release,  stripping  of the  EC  is 
inappropriate in this tissue.  Other sources of UTP should be considered, such as the 
blood stream.
132Difficulties encountered
Stripping and harvesting the LSV inevitably involves instrument handling of 
the  tissue.  Obtaining  skin  biopsies  from  patients  with  CVI  proved  harder  than 
anticipated.  Patients were often reluctant to have an ellipse of skin excised as there 
was  the  possibility  of  a  slightly  greater  scar.  Although  the  operation  is  not 
performed  for  cosmetic  reasons,  an  undeclared  cosmetic  improvement  is  often 
anticipated by the patient.  Our biopsies were taken from the incision made below 
the  knee.  Samples  were  only taken  where  this  occurred  at  sites  of visible  skin 
changes  (CEAP 4a and 4b).  Hence useful  samples were  only  obtained  when an 
incision was made over an appropriately affected skin area in consented patients. 
The skin incision was itself dependent on the pathway the stripper took as it passed 
down the LSV during the surgical procedure.  This would often not be made in an 
affected skin area, or might be above or at knee level.  These reasons explain the 
limited number of samples in the epidermis study.  A larger patient number would 
make  our  results  more  convincing  and  enable  us  to  compare  different  CEAP 
classes.  This could be obtained by continuing the research for a longer period of 
time or by recruiting patients at other hospitals.
Using human tissue samples is complex as there will always be variability 
between individuals.  Whilst known variables have been discussed (eg sex and age), 
many  more  exist  which  have  not  been  mentioned  including  patients  diet  and 
occupation.  Whether these variables are relevant is unknown.  Varicose veins are 
thought to be increased in those who spend much of the day standing and immobile. 
It is possible that our varicose vein group consisted of 2  subdivisions of patients, 
those whose varicose veins are due to their occupation and those who have  SMC 
weaknesses.
Control  LSV  and  skin  tissues  were  obtained  from  patients  undergoing 
CABG surgery.  Naturally these patients are on a long list of cardiac medications 
which  patients  with  CVI  were  not  taking.  Interaction  between  these  drugs  and 
purine receptors can not be excluded.
133A  lack  of visible  varicose  veins  and  a  hand  held  doppler  were  used  to 
exclude  reflux  and  varicose  veins  in  control  patients.  Veins  that  were  slightly 
varicosed with early vein wall structural changes may not have been obvious to the 
naked eye.  If no refluxing valves were detectable, then the vein would have been 
incorrectly labelled as a control vein.
Human penile tissue is a difficult tissue to obtain for research.  With gender 
reassignment  surgery  on the  increase,  its  availability is  greater.  When  sufficient 
patient numbers are present to create a control and a disease group eg diabetes, then 
tumescence can be further evaluated in these diseases.  At present many variables 
exist within the relatively small gender reassignment population.
Conclusion
For many years varicose veins and CVI have troubled patients and doctors. 
Despite new surgical techniques and conservative managements, they continue to 
be  a financial burden on our underfunded National  Health  Service.  For the  first 
time the involvement of purines in the development of these conditions has been 
explored.  The  results  show  changes  in  purine  receptor  activity  and  further  our 
understanding of these conditions.  The identification of the P2Y6 receptor in CSM 
provides more information into our understanding of the tumescence process. New 
targets  for  treatment  have  been  highlighted  through  this  research  which  should 
further encourage work into developing therapies to modify purine target activity.
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157Patient Demographics for Functional Pharmacology
(Chapter 2)
Tables show patient code (identification), pharmacology experiment performed and 
medications taken in patients.
Circular muscle pharmacology in control patients
Patient NA ATP a,p-
meATP KC1 Aspirin P
Blocker Statin
Angiotensin
converting
enzyme
inhibitor
Calcium
channel
blocker
Nitrate
1 X X X X X
2 X X X X X
3 X X X X X X X X
4 X X X X X X
5 X X X X X X X X
6 X X X X X X X X X
7 X X X X X X X X
8 X X X X X
9 X X X X X
10 X X X X
11 X X X X
N=7 N=7 N=7 N=7 N=6 N=10 N=10 N=5 N=4 N=4
Circular muscle pharmacology in varicose patients
Patient NA ATP a,p-meATP KC1 P blocker
1 X X X
2 X X X
3 X X X
4 X X X
5 X X X X X
6 X X X X
7 X X X X
8 X X X X
9 X X X X
10 X X X X
11 X X
12 X X
13 X X
14 X
15 X
16 X
17 X
18 X
t N=13 N=10 N=10 N=14 N=1
158Longitudinal muscle pharmacology in control patients
Patient NA ATP a,p-
meATP
2-
MeSADP KC1 UDP UTP EFS Aspirin P
Blocker
Statin
Angiotension
Converting
Enzyme
Inhibitor
Calcium
Channel
Blocker
Nitrate
1 X X X X X
2 X X X X X X X
3 X X X X X X X
4 X X X X X X X X
5 X X X X X X X
6 X X X X X X
7 X X X X X X X X
8 X X X X X
9 X X X X X X
10 X X X X X X
11 X X X X
12 X X X X X X
13 X X X X X
14 X X
15 X X X X X
16 X X X X X
17 X X X X X
18 X X X X X
19 X X
20 X X X X X
21 X X X
22 X X X
23 X X X X
24 X X X X
25 X X
26 X X X X
27 X X X X X
28 X X X X X
29 X X X X
30 X X X
31 X X X
N=7 N=13 N=7 N=5 N=10 N=5 N=4 N=4 N=26 N=16 N=20 N=15 N=5 N=12
159Longitudinal muscle pharmacology in varicose patients
Patient NA ATP a,p-
meATP KC1
2-
MeSADP
UDP UTP Aspirin
1 X X X
2 X X X
3 X X X
4 X X X X
5 X X X X
6 X X X X
7 X X X X
8 X X X X
9 X X X X
10 X X X X
11 X X
12 X X
13 X X X
14 X
15 X
16 X
17 X
18 X
19 X
20 X
21 X
22 X
23 X
24 X
25 X
26 X
27 X
28 X
29 X
30 X
31 X
N=10 N=13 N=10 N=16 N=4 N=3 N=5 N=1
160